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Abstract 
Five-year survival of oral cancer has remained relatively unchanged despite 
advancements in treatment, mostly because diagnosis is often made at an advanced stage 
of disease. The progression of dysplasia to oral cancer often follows a stepwise progression. 
Histopathology is considered the ‘gold standard’ for diagnosing dysplasia and lesions at a 
high risk of progression to oral cancer, but lends itself to subjectivity. The protein 
biomarker, S100A7, in oral dysplasia and squamous cell carcinoma has shown some 
predictive value for the transformation of dysplasia to cancer. Straticyte, a diagnostic test 
utilizing S100A7 to predict the probability of progression of oral dysplasia to malignancy, 
has recently been developed. Straticyte has never been used to predict progression of oral 
dysplasia alone.  
The objective of this study is to determine if S100A7 is a valuable biomarker in 
predicting the progression of oral dysplasia. We also evaluated if Straticyte is a useful 
tool to predict oral dysplasia progression. 
Formalin-fixed paraffin-embedded (FFPE) specimens were obtained from the 
Tissue Archives of the Division of Oral Pathology at Western University. This study 
included 29 cases of progressing oral dysplastic lesions, 17 cases of non-progressing oral 
dysplastic lesions and 25 control cases of normal tissue. FFPE sections were stained for 
S100A7, cell cycle-related protein cyclin D1, and -Catenin using standard 
immunohistochemistry. Immunoreactivity of S100A7 was evaluated semi-quantitatively, 
using an intensity and proportion scale, as well as quantitatively using an automated 
scoring method (Straticyte) by image analysis. The data was analyzed to compare the 
manual and automated scoring methods and to look for a correlation between S100A7 
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expression and progression of disease. Cyclin D1 and -catenin, other protein biomarkers, 
were also analyzed qualitatively. 
 Mean manual score for the initial biopsy of the progressing, non-progressing and 
control groups was 4.93, 4.83 and 3.52 respectively. The mean Straticyte score for the 
initial biopsy of the progressing, non-progressing and control groups was 25.93, 34.91 and 
30.65. Stepwise regression analysis showed the manual scoring method to be the best 
predictor of lesions being non-progressing compared to controls (p=0.016). The same 
analysis also showed the automated scoring method to be the best predictor of lesions being 
progressing compared to non-progressing (p=0.078).  
Neither the manual or the automated scoring methods proved to be significantly 
superior to the other in predicting progressing of oral dysplasia. S100A7 did not prove to 
be a useful biomarker in predicting progressing of oral dysplasia. More studies are needed 
to determine both the usefulness of S100A7 and Straticyte for predicting progression of 
oral dysplasia.  
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Summary for Lay Audience 
 Oral cancer is a disease that can lead to suffering and pre-mature death. The early 
identification of oral cancer can be difficult and for this reason when oral cancer is detected 
it is often large and has sometimes already spread to other parts of the body. In this study, 
we evaluated if a protein, S100A7, can assist with detecting oral lesions (abnormal oral 
tissue) that have a high likelihood of developing into oral cancer. To explore this, we used 
a staining technique called immunohistochemistry (IHC), that allows for the stain to be 
attached to the protein, S100A7, so that it can be visualized under a microscope. We 
measured the amount of S100A7 both manually (manual method) and using a commercial 
test called, Straticyte (automated method), that uses machine learning.  We compared the 
manual and automated methods to determine if either method was superior at measuring 
the amount of S100A7 and predicting which lesions were high risk.  
 We determined that both methods showed some value; however, neither the manual 
nor the automated method proved to be clearly superior at measuring S100A7 and 
predicting high risk lesions.  
 We concluded that further studies are warranted to determine the value of S100A7 
in identifying high risk lesions and in validating the usefulness of Straticyte. 
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Chapter 1 
1.0 Introduction 
1.1 Oral Cancer  
Cancers of the oral and pharyngeal cavity account for the 6th most common cancer 
worldwide, 90% of which are squamous cell carcinomas (SCC) [1, 2]. SCCs can arise in 
all parts of the upper aerodigestive tract including the lip, oral cavity, nasopharynx, 
oropharynx, hypopharynx and larynx [3]. Of all the anatomical subsites, the oral cavity is 
the most commonly involved site [3, 4]. Oral cancer is believed to be multi-factorial with 
known risk factors (described below). The risk factors are similar for other cancers of the 
head and neck, and most of which are preventable [1, 2]. There are several conditions that 
are potentially malignant and consideration for these lesions must also be given.  
  
1.1.1 Epidemiology/Prevalence of Oral SCC and Oral Potentially Malignant 
Disorders  
According to the World Health Organization (WHO), there is an estimated 529,000 
new cases of oral cavity and oral pharyngeal cancer each year and an estimated 300,000 
deaths per year [2]. Epidemiology of head and neck squamous cell carcinoma (HNSCC) 
can be broken into two major categories: 1) HNSCC due to environmental exposures (ie. 
tobacco, alcohol etc.); 2) HNSCC caused by human papilloma virus (HPV) [5].  
Environmental HNSCC is typically seen in older patients compared to HPV-positive 
HNSCCs, with the median age at diagnosis for environmental HNSCC and HPV-positive 
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HNSCC being 65.6 and 57.8 years, respectively [6]. In addition, tobacco consumption 
appears to be declining in developed countries but rising in underdeveloped countries [7]. 
 Systematic reviews have estimated the worldwide prevalence of leukoplakia and 
oral potentially malignant disorders (OPMD) to be 1.5 and 4.5%, respectively [7, 8]. Asian 
followed by South American and Caribbean countries have the highest prevalence of 
OPMD and this is felt to be due to habits relative to geographic location. The majority of 
cases of OPMD are in individuals older than 50 years [7].  
 
1.1.2 Risk Factors 
 Numerous risk factors have been identified for the development of OSCC [9, 10]. 
According to the WHO, excess alcohol consumption and tobacco use, including smokeless 
tobacco account for approximately 90% of all oral cancer cases [11]. Men have shown to 
have higher incidence and absolute mortality compared to women [11], but women have a 
higher mortality rate, especially amongst non-smokers [12, 13]. Non-homogenous lesions 
also carry an elevated risk relative to their homogenous counterparts [12].   
Other well known risk factors for development of oral SCC (OSCC) are alcohol, 
betel nut and HPV [9]. Although a strong association between tobacco consumption and 
oral leukoplakia has long been realized, an evidence-based causal link is still missing [14]. 
A population-based study in Taiwan with over 2,000,000 participants showed that 
participants who smoked and chewed betel quid had a 2.7 relative risk (RR) of developing 
OPMD or OSCC. This study also showed that betel quid alone compared to smoking alone 
had an increased risk (RR = 2.37) and that smoking compared to non-smoking had 1.17 
RR. The merits of an effective screening program in identifying OPMD and early OSCC 
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were also highlighted in this study [15]. It has been suggested that smoking cessation 
provides a time-dependent benefit to smokers to reduce OPMD/OSCC, such that 10 years 
after quitting smoking, the risk of developing OSCC is similar to a person that has never 
smoked [16, 17]. Smokeless tobacco has also been shown to be a risk factor for OPMD 
and OSCC [17, 18]. A meta-analysis from south Asia showed smokeless tobacco was 
associated with an increased risk of OPMD (odds ratio (OR) = 15.5; 95% confidence 
interval (CI) 9.9 - 24.2). Of the OPMDs, submucous fibrosis had the strongest association 
(16-fold) and leukoplakia the weakest association (4-fold) with smokeless tobacco usage. 
This study also showed a positive exposure-response relationship with risk increasing with 
both duration and intensity of use.  It was also found that females using smokeless tobacco 
were at increased risk of developing OPMD relative to their male counterparts [18].   
 Alcohol is also a well-known independent risk factor for many cancers [10], 
including OSCC, however, its associated risk with potentially premalignant oral epithelial 
lesions (PPOEL)/OPMD is less understood [9].  
It has been shown that combining risk factors can lead to a greater than additive 
risk of developing disease. A large case-control study in India showed a multiplicative 
interaction for smokeless tobacco and alcohol, resulting in a 24-fold increased risk of 
developing OSCC [17]. This study also showed a relationship between the cancer site and 
the risk factor: smokeless tobacco had the strongest association with oral cavity cancer, 
smoked tobacco with pharyngeal and esophageal cancer and betel quid with oral cavity and 
esophageal cancer. All 3 risk factors (chewing (tobacco & betel quid), alcohol and 
smoking) analyzed were shown to increase the risk of oral, pharyngeal and esophageal 
cancer [17]. 
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1.1.3 Oral Cancer as a Stepwise Disease  
The development of oral cancer is thought to proceed in a gradual stepwise fashion 
where degrees of dysplasia are reached prior to malignant transformation, and increasing 
degrees of DNA damage have been correlated to this stepwise progression of cancer [19-
21].  Approximately 90% or more of oral cancers are OSCC. These cancers often start out 
as potentially malignant lesions such as leukoplakia or erythroleukoplakia [22].  
It is estimated that the prevalence of pre-malignant lesions is 2-3% worldwide (with 
no significant difference between developed and developing countries) and the rate of 
transformation of these pre-malignant lesions is estimated to be 2-5% per year [23, 24]; 
unfortunately, at present we do not have a reliable way of predicting which pre-malignant 
lesions will undergo transformation to OSCC [25, 26].  Only about 50% of severe dysplasia, 
30% of moderate dysplasia and less than 5% of mild dysplasia are believed to progress to 
cancer [24]. 
 
1.1.4 Field Cancerization  
The concept of field cancerization (or “field effect”) was first described by 
Slaughter et al. in 1953 [27], which describes underlying genetic and pre-neoplastic 
changes in the tissue that are not readily apparent clinically. This allows for oral cancer to 
develop at multiple sites and lend itself to loco-regional recurrence or the presence of 
‘secondary primary tumours’; the field lesion is believed to be of monoclonal origin and 
has not yet developed the characteristics of invasive growth or metastatic behavior [28].   
Field effects can often occur in tissue that has been deemed “normal” by 
histopathological diagnosis, and not until more advanced molecular techniques are applied 
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does the genetic alterations and field effect become apparent [29]. The study by Tabor et 
al. showed that field effects were present in normal tissue as well as mild, moderate and 
severe dysplasia. Genetic alterations were present in all of the moderate and severely 
dysplastic lesions and about two-thirds of mild dysplastic lesions, suggesting that genetic 
changes lead to progressive disease and more genetic alterations are expected with more 
advanced disease [29].   
It is believed that fields evolve from “patches” which are defined as “groups of cells 
that share a common genotype contiguous at the moment” [30, 31]. These patches can be 
considered a “clonal unit” with genetically altered daughter cells. Due to their genetic 
alteration, these cells exhibit a growth potential advantage and expand to gradually become 
a field, displacing normal cells and tissue laterally. The field can then be subject to multiple 
other genetic hits, resulting in subclones and eventually, enough genetic mutations allow 
for the cells to evolve into an invasive carcinoma [28].   
 
1.1.5 Genetic Mutations Associated with Cancer Progression  
The development of cancer occurs through the accumulation of genetic alterations 
by way of genomic instability that confer succession of clonal expansions and the 
acquisition of the hallmarks of cancer [32]. The hallmarks of cancer are:  sustaining 
proliferative signaling; evading growth suppressors; resisting cell death; replicative 
immortality; angiogenesis; and invasion and metastasis as well as the emerging hallmarks, 
which are evasion of the immune system and reprogramming of energy metabolism [32].  
The accumulation of genetic mutations from normal epithelium to the development 
of metastatic colorectal cancer was eloquently modeled by Fearon and Vogelstein in 1990.  
 
 
6 
They showed that certain genetic alterations/mutations were responsible for the transition 
of normal epithelium to various stages of adenoma and eventually, to a metastatic 
carcinoma. More genetic alterations were observed with the progression to more severe 
lesions. The authors believed that it was the accumulation of certain mutations that was 
important rather than the order in which these mutations were accumulated [33].  Fearon 
and Vogelstein’s model can be seen in Figure 1.1 
Figure 1.1. Genetic changes associated with development of adenocarcinoma 
of the colon. This figure was originally published in Cell. Fearon ER, Volgelstein, B. A 
Genetic Model for Colorectal Tumorigenesis. 1990. 61: p. 759-767. This figure is being 
reproduced for educational purposes only and not for commercial use. Figure is included 
in the M. Sc. dissertation with attribution. 
 
 
 
 Genetic alterations initiating OSCC may result by chance, but most often are caused 
by a lifetime of environmental exposures such as tobacco and alcohol [34]. At a basic level, 
the development of OSCC is caused by an overexpression of oncogenes and a silencing of 
tumour suppressor genes [33, 34]. The genetic alterations involved in the development and 
progression of OSCC and head and neck cancers in general, are abundant, and new 
pathways and interactions are being realized frequently. The development of OSCC is also 
believed to occur from a clonal population that through a series of mutations has conferred 
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a growth advantage over adjacent normal cells [21, 35]. It has been shown that genetic 
alterations accumulate over time and this corresponds to the histopathological diagnosis as 
a lesion progresses from pre-malignant to malignant state [20, 21]. The development of 
clonal populations can occur long before the carcinoma is apparent; latency periods are 
estimated to be in the order of many years [21]. These clonal populations are believed to 
be able to migrate through the tissues which can explain how the entire aerodigestive tract 
can be at risk [21].  
 In 1996, Califano et al. were the first to propose a model for oral carcinogenesis. 
They analyzed 10 loci of commonly known mutations in carcinoma via polymerase chain 
reaction (PCR)–based microsatellite marker analysis. They found that certain genetic 
alterations were present at certain histopathologic stages and formed the initial and 
preliminary model for oral carcinogenesis. In their work, they acknowledged that there will 
undoubtedly be more genetic alterations accounted for in the future [20]. The Califano and 
Sidransky et al. model is shown in Figure 1.2. 
Figure 1.2. Initial model for oral carcinogenesis. This figure was originally published in 
Cancer Research. Califano J, Riet PVD, Westra W, Nawroz H, Clayman G, Piantadosi S, 
Corio R, Lee D, Greenberg B, Koch W, Sidransky D, Genetic progression model for head 
and neck cancer: implications for field cancerization. 1996. 56(11): p. 2488-2492. This 
figure is being reproduced for educational purposes only and not for commercial use. 
Figure is included in the M. Sc. dissertation with attribution. 
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 A more contemporary and simplified model depicting some of the molecular events 
required for the transformation from normal tissue to oral cancer presented by Nikitakis et 
al. is shown in Figure 1.3. These events do not need to occur in a linear fashion, nor are all 
of them required in order for cancer to develop [36].  
 
Figure 1.3. Molecular events associated with oral cancer transformation. This figure 
was originally published in Oral Surg Oral Med Oral Path Oral Radiol.  Nikitakis NG, 
Pentenero, M., Georgaki M, Poh CF, Peterson DE, Edwards P, Lingen M, Sauk JJ. 
Molecular markers associated with development and progression of potentially 
premalignant oral epithelial lesions: Current knowledge and future implications. 2018. 
125: p. 650-669. This figure is being reproduced for educational purposes only and not for 
commercial use. Figure is included in the M. Sc. dissertation with attribution. 
 
 
  
Tumour suppressors are important for regulating the cell cycle, DNA repair 
mechanisms and programmed cell death. If tumour suppressor genes (TSG) are not 
functional, cell growth can go unchecked and this can lead to the development of cancers 
[34]. TP53 is one of the earliest identified TSGs and encodes for the protein p53. The 
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silencing of p53 has been observed in premalignant head and neck lesions [37], HNSCC 
[38] and in numerous other cancers [39]. In a prospective, multi-center study looking at 
survival of HNSCC patients with and without TP53 mutations in their tumours, the authors 
found that patients with any TP53 mutation had decreased overall survival (hazard ratio 
for death, 1.4; 95% CI 1.1 – 1.8; P = 0.009) compared to those without TP53 mutations. 
They also found that disruptive mutations, with more protein disturbance, were particularly 
impactful on survival compared to un-mutated TP53 (hazard ratio 1.7; 95% CI, 1.3 – 2.4; 
P < 0.001); non-disruptive mutations had no association with decreased survival [40].    
 Oncogenes in HNSCC have also been extensively studied. Epidermal growth factor 
receptor (EGFR) works through the tyrosine kinase cascade and has shown to be 
overexpressed in many HNSCC tumours, especially those that are well differentiated [41]. 
Matrix metalloproteinases (MMPs) are a family of matrix-remodeling enzymes believed 
to be involved with many cellular functions such as migration, adhesion and proliferation 
[34]. Various MMPs have been implicated in cancer development. MMP-7 overexpression 
was associated with early stage (I & II) OSCCs, and it was hypothesized that early-stage 
MMP-7 expression is attributed to its anti-angiogenic activity [42].  In another study of 54 
patients with HNSCC, MMP-9 overexpression significantly correlated to lymph node 
metastasis (P < 0.001) [43].  
 Other alterations that have been studied in the development OSCC include loss of 
heterozygosity (LOH), telomerase activity, chromosomal aneuploidy and microsatellite 
instability. Mitochondrial alteration and epigenetic changes, such as hypermethylation are 
also being implicated in cancer progression [35, 36].  A large systematic review found 
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LOH, survivin, MMP-9 and DNA content (non-diploid) to be the strongest predictors for 
malignant transformation, among biomarkers tested [44].  
  
1.1.6 Treatment and Prognosis of OSCC 
One of the greatest challenges in the treatment of OSCC can be in its detection. Pre-
cancerous lesions are often asymptomatic and can be difficult to detect on routine clinical 
exam; for these reasons, oral and oropharyngeal cancer are often not diagnosed until a later 
stage [45].  Early detection is crucial because it is directly correlated to stage de-escalation 
at initial presentation and impacts the 5-year survival [46]. Stage at diagnosis has been 
regarded as the most important prognostic indicator of OSCC [47]. Late stage of initial 
diagnosis can to some extent, be the result of limited biomarkers to detect early disease. 
Despite advances in treatment modalities over the years, the relative 5-year survival 
remains around 50% and appears to be highest for those treated with either surgery alone, 
or in conjunction with radiation [48].  Currently, the mainstay of treatment for OSCC is 
surgery. More advanced disease is generally treated with multi-modal therapy including 
adjuvant radiotherapy with or without chemotherapy in addition to surgery [3].    
For OSCC, surgery will be employed if there is curative intent or in some cases as 
surgical salvage. For curative intent, the goals of surgery are to remove the entire tumour 
while preserving the patients function and maintaining acceptable cosmesis [49].  
Surgery on the primary tumour can be broken down into ablative surgery (removal 
of the tumour) and reconstructive surgery (restoring the defect) [3]. Reconstructive surgery 
can be performed by either primary closure, loco-regional flaps or free tissue transfer [3]. 
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In addition to resection of the primary tumour in the oral cavity, surgery is also used 
to perform a neck dissection in select cases. Neck dissections can be used to remove gross 
nodal disease, or be performed prophylactically/electively if occult disease is suspected [3, 
49].  
In a retrospective study by Quinlan et al, 289 patients with OSCC were analyzed 
over a 12-year period. Ninety-three percent underwent surgical neck dissection and of those, 
66% had nodal involvement and 51% had extracapsular spread, indicating more advanced 
disease. Despite this group of patients being treated with a combination of surgery and 
either chemotherapy and radiation or both, the 5-year loco-regional control and overall 
survival was still only 76% and 51% respectively [50]. This study emphasizes the impact 
advanced disease has on tumour recurrence and mortality.  
Another study by Dillon et al. looked at 20 patients with oral cavity squamous cell 
carcinoma (OCSCC) of the buccal mucosa whom had no clinically identifiable lymph node 
involvement (N0) [51]. Of these 20 patients, 15 (75%) patients underwent elective neck 
dissection (END).  Of the 5 patients who did not undergo an END, all of them (100%) had 
loco-regional recurrence and one (20%) had distant metastasis; compared to only 5 (33%) 
with loco-regional recurrence and 1 (7%) with distant metastasis among the 15 who did 
undergo END. Additionally, the 2 and 5-year survival rates for N0 patients without END 
was 80% and 40% respectively, compared to 93% and 87% for N0 patients who did 
undergo END. Although the sample size was small, these findings not only suggest the 
benefits of performing END in patients without clinically identifiable neck disease, but 
also speak to the ability of cancer to evade detection [51].  
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Chemotherapy is also used in OSCC. At present the cornerstone of chemotherapy 
treatment is cisplatin, however, other agents such as 5-fluorouracil and docetaxel are also 
used. Chemotherapy has various uses in HNSCC which include: definitive primary 
treatment of locally advanced HNSCC in conjunction with radiation; adjuvant treatment 
with post-operative radiation; induction chemotherapy; and treatment of metastatic or 
recurrent disease [5]. In addition to the traditional chemotherapies mentioned, novel 
immunotherapies such as Cetuximab are also being used with favorable results [5, 52].  
 The other main modality of OSCC treatment is radiotherapy (RT). RT can be used 
as primary, adjunctive or salvage therapy. The prescription will vary depend on many 
factors and depending on if the intention is primary, adjunctive or salvage treatment, but 
in general, OSCC will generally receive > 60 Gy [53].  
Radiation technology has improved to deliver the RT with precision using 
intensity-modulated radiotherapy (IMRT), which has reduced complications [53]. Despite 
this, RT still has an abundance of complications associated with it. These complications 
include but are not limited to: caries, periodontitis, thickened mucosal 
secretions/xerostomia, mucositis, soft tissue fibrosis, oropharyngeal candidiasis, 
osteoradionecrosis (ORN), pain and taste dysfunction [54], all of which can adversely 
affect quality of life.  
Osteoradionecrosis is known to be caused by total dosage > 60 Gy, with the 
mandible being at greater risk than the maxilla. There is also some evidence that prior 
mandibular surgery elevates the risk of developing ORN in the mandible [53].  
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Despite advances in the treatment of OSCC, there is still considerable morbidity 
and mortality. More advanced disease requires more extensive treatment which leads to 
greater morbidity. 
 
1.2 Pre-cancer 
1.2.1 Oral Potentially Malignant Disorders (OPMD)/Potentially Pre-Malignant Oral 
Epithelial Lesions (PPOELs) 
  Lesions that have been known to potentially give rise to OSCC have historically 
been described as “premalignant”, however, because only a portion of these lesions will 
progress to OSCC, the more appropriate terminology is to describe these lesions as 
“potentially pre-malignant”. For this reason, the terms “oral potentially malignant disorders 
(OPMD)” or “potentially pre-malignant oral epithelial lesion (PPOEL)” are now preferred 
[13, 55, 56].   
 The term OPMD is used in the latest WHO classification to encompass all 
potentially malignant lesions and disorders [22]. OPMD is defined by the WHO as, 
“clinical presentations that carry a risk of cancer development in the oral cavity, whether 
in a clinical definable precursor lesion or in clinically normal oral mucosa” [22]. The term 
PPOEL has recently been used as a broad term to include both histologic and clinical 
lesions that may progress to malignancy [56].   
 The lesions/disorders commonly referred to as OPMD/PPOEL are: leukoplakia, 
erythroplakia, erythroleukoplakia, oral lichen planus, oral submucous fibrosis (OSF), 
actinic chelitis, palatal lesions of reverse smoking, discoid lupus erythematous, oral 
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dysplasia, chronic candidiasis, smokeless tobacco keratosis, syphilitic glossitis and some 
inherited disorders such as dyskeratosis congenita and Fanconi anemia [13, 22, 56]. 
 
1.2.2 Oral Epithelial Hyperplasia/Dysplasia 
Hyperplasia – is an increase in cell number with regular stratification/architecture and no 
cellular atypia (variations in size or shape of keratinocytes) [26].  
Dysplasia – architectural disturbance accompanied by cellular atypia [26].  
Features of abnormal architecture and cellular atypia are shown in Table 1.1: 
Table 1.1. Architectural and cytological features associated with oral dysplasia.  This 
table was originally produced in Journal of Oral Pathology and Medicine. 
Warnakulasuriya S, Reibel J, Bouqout J, Dabelsteen E. Oral epithelial dysplasia 
classification systems: predictive value, utility, weaknesses and scope for improvement. 
Journal of Oral Pathology and Medicine, 2008. 37(3): p. 127-133. The table is being 
reproduced for educational purposes only and not for any commercial use. Table is 
included in the M. Sc. Dissertation with attribution.  
 
 
In general, the grade of dysplasia corresponds to the number and prominence of 
these features. 
Mild Dysplasia – minimal cytological atypia and architectural disturbance, limited to lower 
1/3 of epithelium [26].  
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Moderate Dysplasia – architectural disturbance extending into middle 1/3 of epithelium. 
Consideration is then given to cytological atypia, in which marked atypia is upgraded to 
severe dysplasia and minimal atypia downgraded to mild dysplasia, despite having 
architectural disturbance extending into the middle 1/3 of epithelium [26]. 
Severe Dysplasia – architectural disturbance extending into the upper 1/3 of epithelium 
[26]. 
 
1.2.3 Risk of Progression of OPMD/PPOELs 
OPMD/PPOELs may have an increased risk of malignant transformation, but the 
difficulty lies in predicting which of these lesions will progress and which will not. There 
are, however, certain clinical characteristics that have shown value in predicting the risk of 
progression. Some of these main clinical characteristics are: size of lesion, 
texture/color/clinical appearance, site, sex and age of the patient [13]. 
For OPMD/PPOELs, the anatomic site in the oral cavity appears to be associated 
with risk of progression, but this is also correlated to the geographic region globally and 
regional lifestyle behaviours. For example, in South Asia where Areca Nut (Betel Quid) is 
frequently consumed, the buccal mucosa is associated with the highest progression. In 
reverse smokers, the palate is often the highest risk site and in the developed world, where 
smoking and alcohol are the most predominant habits, the floor of mouth and lateral tongue 
sites are associated with the highest risk of progression [3, 13]. In a retrospective analysis 
done on 216 patients in Australia, the floor of mouth and lateral tongue were shown to have 
an increased risk of being dysplastic or malignant relative to other anatomic sites (OR  2.6, 
P  = 0.005) [57].  A retrospective study of 630 patients from London and Bristol, UK 
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showed dysplastic lesions to be present in the tongue or floor of mouth 41.5% of the time. 
Although not statistically significant, these sites were also more likely to have severe 
dysplasia than other anatomical sites [58]. The ventral/lateral tongue and floor of mouth 
may be at greater risk for developing more severe disease because of pooled saliva in 
tobacco users. In patients with oral cancer, increased concentrations of nitrites have been 
found in the saliva of tobacco users [59, 60].  
The clinical appearance has also been shown to be predictive of transformation, 
with non-homogenous lesions in color and texture being at greater risk for progression, 
than their homogenous counterparts [12, 57]. Dost et al. found that non-homogenous 
lesions had a significantly increased risk of being dysplastic relative to homogenous lesions 
(OR 4.4, P < 0.005). The authors concluded that any red and white lesion be considered 
high risk and that, because clinical appearance is used to assess long term surveillance of 
a lesion, it is the most reliable and important feature for determining additional surgical 
intervention [57]. Many other studies have also supported this finding that non-
homogeneous lesions are at greater risk for cancer progression than homogeneous lesions 
[12, 61]. 
 Age has also been shown to be a predictor of malignant transformation, with older 
age increasing risk [62]. The exact transformation rate of oral leukoplakia is unknown but 
a systematic review of observational studies found it to be on average 3.8% per year, but 
when evaluated further, the annual transformation rate of homogeneous lesions was 3%, 
while the transformation rate of non-homogeneous lesions was 14.5% (P = 0.001) [62]. 
This same study also showed that oral lesions that are going to transform to malignancy 
will do so most often within the first 5 years after initial presentation [62]. A study by Jaber 
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et al. showed that the average age of a patient with an oral dysplastic lesion was 55 years 
old. In this same study, they also analyzed a younger cohort of patients (< 35 years old) 
because it has been suggested that younger patients exhibit more aggressive disease [63], 
however, Jaber et al. found no significant difference in the grade of dysplasia at diagnosis 
between younger and older patients [58].  
 In studies that have evaluated the relationship between sex and malignant 
transformation, although it is more common for males to have a lesion, proportionately, 
lesions in females are more likely to progress to malignancy [13]. Unfortunately, the 
reasons for this are still largely unknown [13, 62].  In a study of 166 patients with 
leukoplakia from the Netherlands, 16 out of 90 female and 4 out of 76 male patients had 
malignant transformation at a median follow-up of 32 months (P < 0.025). Interestingly, 
female non-smokers were also at greater risk for malignant transformation than their 
smoker counterparts (P < 0.05) [12].  
 Size of lesion is another predictor of malignant transformation. A retrospective 
study by Holmstrup et al. looked at 269 patients and found that  lesions greater than 200 
mm2 have an odds ratio for cancer progression of 5.4 relative to lesions smaller than that 
200 mm2 [61].  
 In a longitudinal observational study at a tertiary oral dysplasia clinic in Liverpool, 
Ho et al. evaluated 92 patients with oral epithelial dysplasia for a median follow-up period 
of 48 months. The investigators estimated a 22% transformation rate at 5 years after initial 
diagnosis. The significant clinical determinants they found to be predictive of malignant 
transformation were: 1) non-smoking status; 2) non-homogeneous appearance; and 3) size 
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greater than 200 mm2. Of borderline significance was high-grade dysplasia. Found to be 
not predictive were gender, age, number of lesions and alcohol consumption [64]. 
 
1.2.4 Diagnosis  
 Currently, for a final diagnosis to be established, histopathology with tissue biopsy 
should be performed. Histopathology remains the gold standard for diagnosis of oral 
epithelial dysplasia, other PPOELs and OSCC. For oral dysplasia, the histopathologic 
grade is used to determine the risk for malignant potential [22]. Unfortunately, 
histopathologic diagnosis of oral dysplasia is subjective and associated with limitations 
such as intra- and inter-observer variations in diagnosis [22, 26, 65-67]. This has led some 
to recommend that observer bias could be reduced if calibration exercises are performed 
amongst pathologists [68].  
 An increasing grade of dysplasia from mild to severe, generally has been associated 
with a higher rate of malignant transformation [69, 70]; however, the difficulty lies in 
predicting which dysplastic lesions will progress to cancer as many have been shown to 
remain static or regress, whereas some non-dysplastic lesions may become malignant [26, 
67]. Because intra- and inter-observer variability complicates the diagnosis of oral 
dysplasia, a binary grading system based on 4 architectural and 4 cytological features with 
the addition of smoking and alcohol consumption has been proposed, and shown to 
improve observer correlation and prognostication [22].  This binary system is shown in 
Table 1.2. 
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Table 1.2. Grading Scheme for Oral Epithelial Dysplasia.  
WHO dysplasia grade: Binary System: 
Mild dysplasia 
Low-grade dysplasia 
Moderate dysplasia 
High-grade dysplasia 
Severe dysplasia 
 
Adapted from the WHO classification of head and neck tumours, 2017 [22].  
 
In a study by Kujan et al., a binary system was utilized (high- and low-grade 
dysplasia) and the authors showed that 80% of high-grade lesions and 15% of low-grade 
lesions transformed to carcinoma. The binary system was found to have a sensitivity and 
specificity of 85% and 80% respectively. The accuracy of the test was 82% [71] and the 
authors concluded that a binary system was useful for predicting malignant transformation 
and accurately differentiating the moderate dysplasia group [71].  
In a follow-up study by Nankivell et al., the same binary system was used in a 
retrospective cohort study with the aim of validating the work of Kujan et al. The authors 
found that although the binary system had improved inter-rater reproducibility compared 
to the standard (non-binary) WHO grading system, the prognostic ability of the binary 
system was the same. The binary system in this study was not useful at accurately 
predicting which moderate dysplasia cases should be placed into low- or high-grade lesion 
categories. The authors also propose that using 4 architectural and 4 cytological features is 
the optimal cutoff for capturing the most malignant transformations, rather than 4 
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architectural and 5 cytological features which the authors claimed was the current standard 
at the time of their study [72]. 
 Another important consideration is that for a biopsy to be performed, the lesion 
must initially be observed clinically.  It has been shown that oral cancer is detected more 
often and at a lower stage in a dental office relative to a medical office. The same study 
showed that lesions identified at a dental office were most often in asymptomatic patients, 
compared to lesions identified at a medical office that were more often symptomatic [47]. 
Lesions that are symptomatic or persistently painful will often be more advanced disease. 
This can lead to a higher stage oral cancer at initial diagnosis and higher mortality rates 
[22, 47].  
The clinical exam is one of the first steps in the diagnostic pathway and the 
importance of performing a thorough exam should not be understated, however, the 
effectiveness and reliability of the clinical exam has been questioned [73]. Complicating 
the clinical exam is there is some evidence that “normal” appearing tissue can harbor pre-
malignant or malignant changes when it is viewed histologically [74]. This phenomenon is 
possible due to the field effect previously discussed [74].  
 
1.2.5 Treatment and Prognosis of Oral Dysplasia 
Cancer development is generally believed to be a stepwise progression, and as a 
result, identifying early precursor lesions, such as oral epithelial dysplasia and intervening 
before cancer has progressed is ideal [22, 75]. For the treatment of oral dysplasia there are 
no unanimously agreed upon guidelines as no randomized controlled trials (RCTs) have 
been conducted, making this topic an area of controversy [75]. The main difficultly is with 
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predicting which pre-malignant lesions will go on to develop cancer and the impact of 
interventions on mitigating this risk is still uncertain.  In short, there is no consensus on 
treatment or even follow-up for patients with oral epithelial dysplasia [76].  
Numerous interventions for oral epithelial dysplasia have been tried; these include 
surgical, medical and complementary.  Medical and complementary interventions that have 
been attempted, include: Vitamin A and retinoids; beta carotene and carotenoids; non-
steroidal anti-inflammatory drugs (ie. ketorolac and celecoxib); green tea extracts; EGFR 
inhibitors/antagonists, p53 modulators, bleomycin and Bowman-Birk inhibitor; however, 
these have either been experimental, ineffective or poorly tolerated in the treatment or 
prevention of oral dysplasia [77-79]. In 2016, a Cochrane systematic review found no 
substantial evidence to support the use of medical and complementary therapies. This 
report also highlighted that, in general, there are few high quality studies on the treatment 
of oral dysplasia and there are no RCTs that have evaluated the impact of surgical 
intervention on dysplasia progression [77].  As it stands, oral epithelial dysplasia is usually 
treated with surgery or active surveillance. Surgery primarily includes excision with a 
scalpel, laser or cryosurgery [79].   
Mehanna et al. in a systematic review and meta-analysis of observational cohort 
and case-control studies of 992 patients, found the mean malignant transformation rate to 
be 12.1% over an average of 4.3 years. The mild and moderate oral dysplasia transformed 
at a much lower rate of 10.3%, compared to severe dysplasia and carcinoma in situ that 
transformed at 24.1%. This meta-analysis was also supportive of surgical excision as an 
intervention, with malignant transformation occurring in 14.6% of the observation group 
and 5.4% of the surgical group [70].  
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However, not all studies are supportive of surgery for the prevention of malignant 
transformation. A retrospective study performed by Homlstrup et al., examined two groups 
of patients: surgical intervention (ie. complete excision) vs. surveillance and found that 
surgery did not appear to have a protective role in malignant transformation [61]. The 
authors of this study suggested that this result could be due to field cancerization.  
Although there are no specific guidelines for how to best manage oral epithelial 
dysplasia, the main treatments are surgery and surveillance [80]. The Liverpool protocol is 
a well-known algorithm for managing oral epithelial dysplasia and most 
surgeons/clinicians around the world follow some construct of similarity [75]. The 
Liverpool algorithm is shown in Figure 1.4. 
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Figure 1.4.  The Liverpool management algorithm for oral epithelial dysplasia. This 
table was originally produced in Oral Oncology. Field EA, McCarthy C, Ho MW, Rajlawat 
BP, Holt D, Rogers SN, Triantafyllou A, The management of oral epithelial dysplasia: The 
Liverpool algorithm. Oral Oncol, 2015. 51: p. 883-887. This figure is being reproduced 
for educational purposes only and not for any commercial use. Figure is included in the M. 
Sc. dissertation with attribution.  
 
 In the Liverpool protocol, if it is amenable to the patient’s function, all moderate 
and severe dysplasia, carcinoma in situ (CIS) and mild dysplasia that have predictive risk 
factors, will undergo wide local excision. The only group that can go into routine 
monitoring are the mild dysplasia without predictive risk factors. In areas where the lesions 
are deemed to be too large or involving vital structures, lesions will sometimes be observed 
and re-biopsied if there is any worrisome clinical change. Lifetime follow-up with the 
multi-disciplinary team/oral dysplasia clinic is implemented for moderate dysplasia, severe 
dysplasia, CIS and mild dysplasia with predictive risk factors. Mild dysplasia without 
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predictive risk factors will be followed for 5 years and then may be discharged back to the 
general dentist for ongoing follow-up [75].  
 Another proposed algorithm from Awadallah et al. for the management of oral 
epithelial dysplasia is shown in Figure 1.5. 
Figure 1.5.  Awadallah Management Algorithm for Oral Epithelial Dysplasia. This 
table was originally produced in Oral Surg Oral Med Oral Pathol Oral Radiol. Awadallah 
M, Idle M, Patel K, Kademani D. Management update of potentially pre-malignant oral 
epithelial lesions. 2018. 125(6): p. 628-636. This figure is being reproduced for educational 
purposes only and not for any commercial use. Figure is included in the M. Sc. dissertation 
with attribution. 
 
 
 The Awadallah algorithm is like the Liverpool algorithm, with the main differences 
being that although both favor lifelong follow-up for all dysplastic lesions, the Awadallah 
algorithm has follow-up at more frequent intervals. Specific mention to the size of the 
clinical margin of normal tissue for moderate and severe oral dysplasia is also mentioned 
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in the Awadallah algorithm. Despite these minor differences, both algorithms emphasize 
the importance of regular and routine surveillance and surgical excision for any dysplastic 
lesion that is even remotely worrisome [56, 75]. 
In a study evaluating the value of having a multidisciplinary center monitor and 
treat oral dysplasia, Ho et al. showed that cancers at a multidisciplinary center were 
diagnosed at an earlier stage allowing for less extensive interventions and favorable long-
term outcomes. The study had 91 patients being followed for oral dysplasia, of which 23 
(25%) developed malignancy, with stage 1 disease.  Twenty-one were treated with wide 
local excision, 2 were treated with ablation and reconstruction and 2 were treated with 
adjuvant radiotherapy. With a median follow-up of 24 months, overall survival was 96% 
and disease-free survival was 100%. Three patients had local recurrence, 1 had regional 
recurrence and 5 patients had secondary primary tumours [81]. This study favors oral 
epithelial dysplasia being monitored in a specialist/multidisciplinary clinic.  
  
1.2.6 Molecular Markers Associated with Development and Progression of PPOELs  
Numerous molecular markers have been evaluated in PPOELs. Some of the main 
markers that have been evaluated are: DNA aneuploidy; loss of heterozygosity (LOH); cell 
cycle, proliferation and apoptosis-related molecules such as Ki-67, cyclin D1, p16 and p53; 
telomeres and telomerases involved with cellular immortality; vascular endothelial growth 
factor A (VEGF-A) for angiogenesis; cell adhesion related molecules such as E-cadherin 
and -catenin; degradative enzymes such as MMPs; signaling pathway molecules such as 
EGFR; epigenetics such as histone modification,  micro RNAs (miRNAs) and 
hypermethylation; cancer stem cells; DNA damage response biomarkers and S100A7 [36]. 
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1.3 Biomarkers Associated with Oral Dysplasia  
1.3.1 S100A7 
In 1991, S100A7 was originally identified to be up-regulated in psoriatic 
keratinocytes and it was given the name “Psoriasin” [82]. At this time, it was postulated to 
be involved in inflammatory cascades [82] and has since been discovered to be involved 
in chemotaxis of neutrophils and helper T cells [83]. S100A7 is an 11.4-kDa Ca2+ binding 
protein made up of 101 amino acids and encoded by S100A7 gene on the epidermal 
differentiation complex on chromosome 1q21 [36, 82-88]. It has two Ca2+ binding sites of 
the helix-loop-helix (EF – hand type) conformation [89]. This protein is involved in many 
inflammatory processes [84] such as systemic lupus erythematous (SLE) [90] and atopic 
dermatitis [91]. S100A7 is found in both the nucleus and cytoplasm and is involved in 
regulating many cellular processes, such as proliferation and differentiation [84].  S100A7 
expression has been observed to be predominantly confined to the epidermis of epithelial 
tissue and in psoriatic patients, it was observed to be mostly in the mid to upper zones of 
the epidermis [92]. In normal epithelium, S100A7 expression is also greatest in the spinous 
layer, where it is found mostly on the cytoplasmic membrane, but can also be found in 
small amounts in the cytosol of the basal layer [93]. Higher expression in the upper, well-
differentiated epidermal layers, rather than the basal layer, suggests that S100A7 has more 
of a role in cellular differentiation than it does in proliferation [93, 94]. The expression of 
S100A7 has also been found to be higher in CIS, keratoacanthoma and differentiated SCC 
than it is in undifferentiated SCC and undifferentiated basalioma, supporting that S100A7 
is involved in keratinocyte differentiation [95].  
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S100A7 has been identified in numerous cancers, such as SCC of bladder [96] and 
lung [97], breast carcinoma [98] and OSCC [99]. Studies showing higher S100A7 
expression in ductal carcinoma in situ (DCIS) than the adjacent invasive breast cancer 
suggest a role of S100A7 in early carcinogenesis [98]. S100A7 has also been speculated to 
have a protective function against cancer cell invasion [100]. The S100A7 gene has been 
shown to control proliferation and invasive potential of breast cancers through its activation 
of nuclear factor-kappa B (NF-), VEGF and MMP-9 [101]. In addition, S100A7 in 
breast cancer increases reactive oxygen species (ROS) and VEGF in a paracrine manner 
through the receptor for advanced glycation end products (RAGE), leading to angiogenesis 
[102].  Evidence also shows that S100A7 may possess differential activities; through the 
-Catenin/T-cell factor 4 pathway, S100A7 enhances tumourigenesis in estrogen receptor-
negative cells but inhibits tumourigenesis in estrogen receptor-positive cells [89].  
S100A7 is known to have effects both intra and extracellularly; extracellularly 
S100A7 interacts with matrix and induces the secretion of soluble factors involved with 
immune cell recruitment, tumour cell migration/invasion, matrix remodeling and 
angiogenesis [103]. The use of monoclonal antibodies against S100A7 has shown 
reduction in tumour growth and inhibition of invasion [103].  
In HNSCC, S100A7 was originally identified in 2008 by proteomic analysis, in 
which differential expression of S100A7 was found in patients with HNSCC compared to 
healthy controls [104].  S100A7 is thought to play a role in local tumour progression by 
activating the mitogen-activated protein kinase (MAPK) signaling pathway via the RAB2A 
pathway in OSCC [99]. In another study, S100A7 was responsible for anoikis resistance 
and tumourigenesis in oral cancer cells. This same study showed high expression of 
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S100A7 measured in the saliva of individuals with HNSCC  and absence of S100A7 in 
saliva from healthy controls, prompting the authors to suggest that S100A7 may have 
utility in both detection of early cancers and in long-term surveillance for individuals with 
prior disease [105].  
A retrospective cohort study evaluated the utility of 3 protein biomarkers to predict 
recurrence-free survival of OSCC patients; one of these biomarkers was S100A7. Based 
on the algorithm, a biomarker signature score was generated which stratified the OSCC 
patients into two groups: high and low risk for recurrence. There were two separate 
populations the evaluators examined, a population from India and one from Canada. In the 
Indian population, the disease-free survival at 3 years for the high- and low-risk groups 
was 30% and 71%, respectively, showing good utility of the biomarkers for predicting 
recurrence.  In the Canadian population, the disease-free survival at 3 years for the high- 
and low-risk groups was 32% and 50%, respectively [106]. Although the algorithm 
performed better at predicting recurrence in the Indian population, this study still shows 
that S100A7 may have some clinical utility in predicting recurrence risk. Multi-center, 
prospective studies would be helpful in validating this.  
S100A7 expression has been evaluated in both PPOELs and HNSCC. In 2010, 
Tripathi et al. discovered overexpression of S100A7 in oral dysplasia/hyperplasia and 
HNSCC as compared to normal tissue [107]. Through correlation studies, they also found 
nuclear accumulation of S100A7 to be a positive predictor of poor prognosis in HNSCC 
patients [107]. This study also detected S100A7 overexpression in squamous cell 
hyperplasia with no evidence of dysplasia [107]. In 2014, Kaur et al. evaluated the 
expression of S100A7 in patients with oral lesions having histopathological evidence of 
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dysplasia and a known clinical outcome [108]. They found that most cases of dysplasia 
that progressed to malignancy exhibited S100A7 overexpression. Specifically, cytoplasmic 
S100A7 was shown to be the most significant risk factor for cancer development, having a 
positive predictive value (PPV) of 75.6% and a negative predictive value (NPV) of 78.5% 
[108].  
 
1.3.2 Beta-catenin 
-catenin was first identified in the 1980’s as being associated with Uvumorulin 
(E-Cadherin), a Ca2+ -dependent cell adhesion molecule and integral membrane protein 
[109].  -catenin (95 kDa) is an oncogene that is the central player in the canonical Wnt 
signaling cascade [110, 111]. The Wnt--catenin pathway is involved in stem cell 
maintenance, cell survival, migration, motility, proliferation and fate determination during 
development [112]. -catenin is a cytoplasmic protein that in the absence of Wnt signaling 
will be targeted for degradation through the ubiquitin-proteasome pathway via its 
association with the adenomatous polyposis coli (APC) protein and glycogen synthase 
kinase 3 (GSK 3) complex.  However, in the presence of Wnt signaling, -catenin 
translocates to the nucleus where it activates target genes associated with cancer 
development and progression [110, 113].  
-catenin also exists in a cadherin-bound form and couples the cadherin proteins to 
cytoskeletal proteins [110, 111]. Loss of the -catenin-cadherin adhesion complex can lead 
to increased cytoplasmic levels of -catenin which can enhance oncogenic activity of -
catenin [112]. -catenin was shown to be downregulated in esophageal, colon and stomach 
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cancers relative to normal controls, suggesting that the -catenin/E-cadherin complex is 
important for preventing cellular invasion and metastasis [111].  
 In a study evaluating the expression of the cadherin-catenin complex in oral 
dysplasia and OSCC, loss of the cadherin-catenin complex was found to be a late event in 
tumourigenesis and was associated with invasion, metastasis and loss of differentiation 
[114]. 
 One study has shown -catenin to have a reciprocal relationship to S100A7, such 
that S100A7 is believed to be a negative modulator of -catenin, by targeting it for 
degradation via a non-canonical mechanism that is independent from GSK 3 mediated 
phosphorylation. In the same study, the overexpression of -catenin was also shown to 
inhibit S100A7 [94]. The authors suggested that Wnt--catenin is the ‘master-switch’ for 
transitioning from cellular differentiation to proliferation and that S100A7 functions as a 
tumour suppressor to prevent this through its negative modulation of -catenin [94].  
 
1.3.3 Cyclin D1 
 Cyclin D1 is a member of a family of proteins involved in cell cycle progression 
[115]. Cyclin D1 is encoded by CCND 1, located on chromosome 11q13 and is principally 
responsible for promoting the transition between the G1-S phase of the cell cycle  [116]. 
In relation with its catalytic partners, such as CDK 4 and CDK 6 (cyclin dependent kinase 
4 and 6), cyclin D1 promotes progression through the restriction point of the cell cycle 
[117, 118]. Progression through the restriction point of the cell cycle is thought to be caused 
by the effect of cyclin D1 and its associated kinases on retinoblastoma protein (pRB), a 
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tumour suppressor protein. Cyclin D1 and CDK 4 and CDK6, phosphorylate pRB, 
removing its suppressive effect on the cell cycle [119].  
Cyclin D1 has been linked to many oncogenic functions such as proliferation, cell 
growth, mitochondrial modulation, DNA damage response, migration and cellular 
differentiation [116].  Cyclin D1 overexpression is associated with larger tumour size, 
advanced clinical stage, lymph node involvement, poor differentiation and lack of response 
to treatment, all of which impart a poor prognosis [116, 120]. 
 Cyclin D1 has been evaluated in oral epithelial dysplasia as well as OSCC. A study 
by Rousseau et al. found similar levels of cyclin D1 protein in all grades of dysplasia and 
OSCC [121]. The authors also concluded that approximately 10% of epithelial cells in 
normal tissue produce cyclin D1 and its expression is confined to the basal and parabasal 
layers in normal tissue but can be found higher up in the epithelium in dysplasia [121].  
 Another study by Shintani et al. found cyclin D1 to be highly expressed in OSCC, 
but not expressed in dysplastic lesions, and instead, cyclin E was found to be overexpressed 
in dysplastic lesions. These authors concluded that cyclin D1 may play a role once OSCC 
has been established, but cyclin E is more important in the pre-cancerous state [122]. 
 Two recent systematic reviews and meta-analysis evaluating the utility of protein 
biomarkers in predicting OSCC suggest that cyclin D1 may be a useful biomarker [123, 
124]. Both reviews reported that the quality of studies is low and that more high quality, 
multi-center research is still required to validate the utility of cyclin D1 [123, 124].  
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1.4 Straticyte 
1.4.1 Straticyte Test to Predict Oral Dysplasia Progression 
S100A7 expression has previously been associated with HNSCC [104] and 
suggested to be associated with a poor prognosis in HNSCC [107]. S100A7 overexpression 
has been suggested to be associated with oral dysplasia progression to malignancy [108].  
Straticyte is a diagnostic test, developed by Proteocyte AI (Toronto, Ontario, 
Canada), that quantifies the expression of S100A7, to predict the risk of transformation 
from pre-cancerous lesions to invasive malignancy [125]. Hwang et al. have evaluated 
Straticyte and claim it classifies pre-cancerous lesions more accurately than 
histopathological grading for risk of progression to cancer over a 5-year period [25]. 
However, a follow-up study by Hwang et al. was found to contain errors and the work was 
subsequently retracted [126-128].  
 Straticyte uses image analysis to quantify the expression of S100A7 and 
proprietary algorithms based on a clinical reference database of 150 cases, to predict the 
progression of pre-malignant to malignant disease [25, 125, 129]. Individualized risk 
assessments are then generated that provide a risk prediction for progression to cancer over 
5-years.  
 Although Straticyte has previously shown value in predicting the progression of 
oral dysplasia to malignancy [25], to our knowledge it has never been evaluated in 
predicting progression of oral dysplasia alone.  
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Chapter 2 
2.1 Hypothesis 
 S100A7 levels will be greater in oral epithelial dysplastic lesions that undergo 
progression compared to lesions that do not undergo progression.  
 
2.2 Rationale 
In addition to the difficulty of clinically detecting a precancerous/cancerous lesion, 
there is also often disagreement between pathologists regarding the histologic diagnosis 
once the biopsy has been obtained [65, 66]. As the diagnosis of oral cancer is a subjective 
process, the search for an objective and quantifiable measure continues to be an important 
focus for pre-cancer detection and treatment.   
The high morbidity and mortality of oral carcinomas along with the low 
transformation rate of PPOELs create a strong demand for reliable early detection [25]. 
Early detection through biomarkers should lead to more effective disease management. 
Biomarkers have the potential to assist with diagnosing OSCC at earlier stages or 
identifying pre-malignant conditions before they have transformed to cancer.  
Incorporation of reliable biomarkers into the diagnosis of pre-malignant and malignant 
lesions will add accuracy and objectivity to the process.   
  The relatively recent utilization of protein biomarkers for their role in predicting 
transformation of pre-malignant oral lesions has produced some favorable results. One of 
these biomarkers, S100A7 may be paramount in providing researchers and clinicians with 
the utility to objectively evaluate pre-malignant lesions for risk of progression and 
ultimately transformation.  
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2.3 Aims 
1) To show that there is a greater expression of S100A7 in potentially malignant 
lesions than in normal epithelial control tissues.  
2) To show that there is a greater expression of S100A7 in potentially malignant 
lesions that progress to a higher-grade of dysplasia than in lesions that do not 
progress.  
3) To test whether an image-based algorithm utilizing S100A7, Straticyte, in 
potentially malignant lesions accurately predicts progression.  
4) To evaluate the expression of -catenin and cyclin D1 in potentially malignant oral 
lesions.  
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Chapter 3 
 
3.0 Materials and Methods 
3.1 Case Selection 
Studies were initiated after receiving approval from the Office of Human Research 
Ethics at Western University (REB #105954). Cases of potentially malignant oral epithelial 
lesions from 2002 – 2017 were retrieved using the Oral Pathology, Schulich School of 
Medicine & Dentistry, Western University database. Cases were selected by searching 
specimen identification numbers from lists of cases arranged according to their 
pathological diagnosis (ie. mild, moderate, severe dysplasia or CIS). Inclusion criteria 
required subjects to undergo multiple biopsies (ie. at least 2 biopsies), from the same 
anatomic site over a period of time.  Specimen paraffin tissue blocks were then retrieved 
from the storage archives of the Division of Oral Pathology at Western University. Hospital 
cases that were not available from the Western University site, were acquired from London 
Health Sciences Centre, University Hospital. 
3.1.1 Progressing, Non-progressing & Control Cases 
Subjects were then organized into progressing and non-progressing cases. A 
progression was defined as any subject who had a subsequent biopsy that was diagnosed 
with a higher degree of dysplasia than the previous biopsy. A non-progression was defined 
as any subsequent biopsy that either had a lower or equal grade of dysplasia than the 
previous one.  
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Twenty-five cases were selected to be used as controls. These cases consisted of 
hyperkeratosis. The control cases were a single biopsy from an individual at one point in 
time. Each case was verified by histological diagnosis by an experienced oral 
histopathologist, and categorized as “progressing”, “non-progressing” and “control”. The 
distribution of the included cases and the number of biopsies in each category in this study 
is presented in Table 3.1. 
Table 3.1. Distribution of cases included in the study 
 
Progression Non-progression Controls 
Cases 29 17 25 
Biopsies 66 36 25 
 
The total number of cases and biopsies included in the study was 71 and 127, 
respectively. Each case was comprised of at least two biopsies and as many as five biopsies 
over a non-specified time interval.  
The 29 progressing cases came from 27 subjects. Three subjects had multiple 
progressions from the same location over a period of time. For the progressing group, cases 
#4 & 5 were from the same subject, cases #7 & 8 were from the same subject and cases 
#22 & 23 were from the same subject.   
The 17 non-progressing cases came from 17 different subjects. Case #10 of the non-
progressing group had an initial biopsy that was ‘mild dysplasia’ and a subsequent biopsy 
that was ‘mild dysplasia with focal moderate dysplasia’, but was re-evaluated by an 
experienced oral histopathologist and deemed not to contain moderate dysplasia in the 
subsequent biopsy.  
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One subject was included in both the progressing and non-progressing groups as 
this subject had separate lesions from different locations in the oral cavity, one of which 
progressed (case #11 of progressing group) and the other that did not (case #2 of non-
progressing group). 
Case #9 (progressing group) had four biopsies from the same site at different 
points in time, that when compared to the initial biopsy, each represented a progression. 
 
3.1.2 Specimen Location within the Oral Cavity  
 No region within the oral cavity was excluded from the study. Anatomic locations 
that were deemed to be similar were clustered into a categorical grouping. This categorical 
grouping was based on both proximity within the oral cavity and on how the location would 
most often be described on the pathology report from the referring surgeon. The various 
anatomic locations and their categorical grouping are shown in Table 3.2. 
Table 3.2. Location of biopsy and corresponding category 
Location Location Category 
FOM 1 
Ventral 
Tongue/FOM 1 
Ventral Tongue  1 
Soft Palate 2 
Ventrolateral 
Tongue 3 
Lateral Tongue 3 
Gingiva 4 
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Retromolar Pad 5 
Buccal Mucosa 6 
Lower Lip 7 
Dorsal Tongue 8 
 
3.1.3 Demographic Data 
From the pathology reports, demographic data such as sex and age at time of biopsy, 
was obtained. These reports also provided the date of biopsy, location of biopsy and the 
diagnosis. The demographic data for the initial biopsy of the progressing, non-progressing 
and control cases included in the study is shown in the Tables 3.3, 3.4 & 3.5. 
Table 3.3. Demographic data for progressing cases of oral epithelial dysplasia 
Case  Diagnosis Location Sex Age 
1 moderate to severe dysplasia ventral tongue  F 53 
2 Mild atypia with hyperkeratosis FOM F 39 
3 Mild to moderate dysplasia FOM M 60 
4 moderate to severe dysplasia FOM M 70 
5 moderate to severe dysplasia with focal CIS FOM M 66 
6 mild to moderate dysplasia lateral tongue M 69 
7 Verrucous hyperplasia with early verrucous carcinoma FOM F 46 
8 mild dysplasia ventral tongue/FOM F 49 
9 moderate dysplasia lateral tongue M 61 
10 hyper-orthokeratosis with mild dysplasia lateral tongue M 73 
11 mild dysplasia right lateral tongue M 68 
12 moderate dysplasia ventral tongue  M 49 
13 mild dysplasia FOM F 53 
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14 amalgam tattoo FOM F 78 
15 mild to moderate dysplasia lateral tongue F 71 
16 Mild to moderate dysplasia lateral tongue M 47 
17 verrucous hyperplasia with moderate epithelial dysplasia lateral tongue M 88 
18 moderate dysplasia ventral tongue M 35 
19 mild dysplasia buccal mucosa M 73 
20 mild dysplasia lateral tongue M 65 
21 mild dysplasia ventrolateral tongue M 59 
22 severe dysplasia lateral tongue F 75 
23 mild to moderate dysplasia lateral tongue F 78 
24 moderate dysplasia FOM M 62 
25 mild dysplasia ventral tongue  F 30 
26 mild dysplasia FOM F 35 
27 mild dysplasia lateral tongue M 55 
 27 mild dysplasia lateral tongue M 55 
28 mucositis with hyperorthokeratosis lateral tongue M 69 
29 severe dysplasia lateral tongue F 41 
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Table 3.4. Demographic data for non-progressing cases of oral epithelial dysplasia 
Case Diagnosis Location Sex Age 
1 moderate to severe dysplasia soft palate F 74 
2 mild dysplasia left lateral tongue M 64 
3 CIS lateral tongue M 68 
4 moderate dysplasia soft palate F 60 
5 moderate to severe dysplasia lateral tongue M 66 
6 hyperparakeratosis with chronic mucositis  lateral tongue F 31 
7 moderate to severe dysplasia lateral tongue M 37 
8 moderate dysplasia ventrolateral tongue F 51 
9 moderate dysplasia retromolar pad F 66 
10 mild dysplasia lateral tongue M 57 
11 mild dysplasia FOM M 58 
12 mild dysplasia soft palate M 71 
13 mild dysplasia lateral tongue M 66 
14 hyperkeratosis with mild epithelial atypia and chronic mucositis  lateral tongue F 40 
 14 hyperkeratosis with mild epithelial atypia    lateral tongue F 40 
15 mild dysplasia FOM M 60 
16 mild dysplasia lateral tongue F 65 
17 mild dysplasia ventral tongue  M 63  
 
 
Table 3.5. Demographic data for controls/normal/hyperkeratosis cases 
Case  Diagnosis Location Sex Age 
1 Hyperkeratosis with mild epithelial dysplasia soft palate F 48 
2 hyperkeratosis lateral tongue F 61 
3 Hyperorthokeratosis gingiva M 35 
4 hyperkeratosis retromolar pad M 59 
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5 Hyperkeratosis  lateral tongue M 53 
6 hyperkeratosis gingiva F 43 
7 hyperkeratosis gingiva F 51 
8 hyperkeratosis FOM M 30 
9 hyperkeratosis retromolar pad M 41 
10 hyperkeratosis gingiva M 48 
11 hyperkeratosis lateral tongue F 66 
12 hyperorthokeratosis retromolar pad M 60 
13 Hyperparakeratosis ventral tongue M 50 
14 Hyperkeratosis epithelial architectural atypia FOM F 67 
15 Hyperparakeratosis  ventral tongue F 15 
16 hyperkeratosis lateral tongue F 46 
17 hyperkeratosis  lateral tongue M 36 
18 hyperkeratosis lateral tongue F 72 
19 hyperkeratosis lateral tongue F 68 
20 hyperkeratosis dorsal tongue M 40 
21 hyperparakeratosis lateral tongue M 24 
22 hyperkeratosis ventral tongue F 53 
23 hyperparakeratosis lateral tongue M 66 
24 hyperkeratosis lateral tongue M 68 
25 hyperkeratosis lateral tongue F 60 
 
 
3.1.3.1 Additional Demographic & Risk Factor Data 
Because the data provided from the pathology reports was limited, an attempt to 
gain additional demographic and risk factor data took place. Using a secured hospital 
account, a letter was sent to all referring surgeons requesting the following information:  
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• Was there a history of tobacco use? 
• Was there a history of alcohol use (> 3 drinks/day)? 
• Was the lesion localized or diffuse at the time of biopsy? 
• Is the patient alive or deceased at present? 
• Is the patient still undergoing surveillance? 
• Is the lesion still present? 
• When was the patient last seen? 
 
3.1.4 Diagnosis Category and H&E Evaluation 
Once all the subjects/biopsies were selected for the study, the Hematoxylin and 
Eosin (H&E) histopathological slides were retrieved and analyzed under the light 
microscope with an experienced oral histopathologist and the graduate student author to 
ensure agreement with the reported diagnosis. Biopsies consisting of an area deemed to be 
‘focal’ were carefully evaluated to ensure that they were placed into the most representative 
diagnosis category for the study.  
The diagnosis categories included in the study can be seen in Table 3.6. 
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Table 3.6. Histopathological diagnosis and corresponding diagnosis category 
Diagnosis Diagnosis Category 
Other* 1 
Mild Dysplasia** 2 
Mild to Moderate Dysplasia 3 
Moderate Dysplasia 4 
Moderate to Severe Dysplasia 5 
Severe Dysplasia 6 
CIS 7 
Focal Microinvasive SCC 8 
* Hyperorthokeratosis, fibrous hyperplasia, mucositis with architectural atypia, ulcerative 
granuloma with stromal eosinophilia, amalgam tattoo 
** A single case of verrucous carcinoma which is considered to be a low-grade lesion was 
placed into this category 
 
3.2 Binary Scoring 
 An experienced histopathologist and the graduate student author evaluated the H&E 
sections for the progressing and non-progressing cases used in the study and reclassified 
them according to the 2017 WHO binary ‘high/low’ risk binary scoring system. To be 
classified as a ‘high-risk’ lesion, at least 4 architectural and 4 cytological criteria were 
required. Criteria can be seen in Table 1.1 in Chapter 1. The experienced oral 
histopathologist and the graduate student author evaluated the lesions independently and 
were blinded to both the histological diagnosis and the score designated by the other person. 
Inter-rater reproducibility, evaluating consistency in scoring between the oral pathologist 
and the graduate student author was also measured.  
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3.3 S100A7 Staining and Analysis  
3.3.1 Specimen Preparation 
 Paraffin tissue blocks were prepared using a microtome to ensure tissue slices were 
representing the full specimen. The blocks were then placed on ice bath for 20 minutes to 
ensure tissue hydration. Numerous tissue slices for each of the specimen were created and 
placed into a water bath (45C), before they were placed onto charged slides and set into a 
warm oven until specimen were used for immunohistochemistry (IHC).  
3.3.2 Establishing Optimal Staining Conditions  
 Prior to performing IHC on the study specimen, optimal experimental conditions 
needed to be established. To do this, trial runs were performed to compare pressure cooker 
settings at 125C and 112.5C for antigen retrieval. In addition, buffer that contained Tris 
(Sigma Aldrich, St. Louis, MO, USA) + EDTA  
(Sigma Aldrich, St. Louis, MO, USA) + Tween 20 (Sigma Aldrich, St. Louis, MO, USA) 
and Tris + EDTA without Tween 20 were compared for heat-induced antigen retrieval. 
These trial runs determined that tissue was preserved best with Tris + EDTA + Tween 20 
and pressure cooker settings at 112.5C; these were the conditions that were used for all 
experiments.  
3.3.3 Immunohistochemistry (IHC) Protocol for S100A7 
 Rehydration was performed in the following manner: 100% xylene x 3 (5:5:3 
minutes); 100% ethanol x 2 (2:1 minutes); 95% ethanol x 2 (2:1 minutes); 70% ethanol for 
2 minutes and then distilled water (dH2O) for 2 minutes. Once brought to water, the slides 
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were placed in pressure cooker set to 112.50C with Tris – EDTA buffer pH 9.0 with 0.05% 
tween 20. 
 Staining was performed in the following manner:  slides were cooled down in 
running tap water and washed three times for three minutes each in TBS-T with gentle 
agitation. Next, blocking buffer was applied for 15 minutes using MACH 4 Background 
Punisher (Inter Medico, Markham, ON, Canada, Catalogue number: BC-BP974L) (125 l 
per slide). Blocking buffer was then drained from the slides and S100A7/Psoriasin mouse 
monoclonal IgG1 Kappa (Novus Biologicals Canada, Oakville, ON, Canada, Catalogue 
number: NB 100-56559; clone: 47C1068), diluted to 1:2000 in 1.5% horse serum (VWR 
International, Toronto, ON, Canada, Catalogue number: 10015-630) in TBS was then 
added. Negative controls received 1.5% horse serum alone. Slides were incubated at room 
temperature for 1 hour and then rinsed three times, for three minutes in TBS-T with gentle 
agitation. Upon completion of incubation, the slides were placed in 3% H2O2 in TBS for 
10 minutes to block peroxidase activity, and then washed for 3 minutes once with TBS-T. 
Next, 125 l of MACH 4 Mouse Probe (Inter Medico, Markham, ON, Canada, Catalogue 
number: BC-M4U534L) was then applied and the specimen were incubated for 15 minutes. 
Slides were then washed three times for 3 minutes each in TBS-T. Then 125 l of MACH 
4 HRP Polymer (Inter Medico, Markham, ON, Canada, Catalogue number: BC-M4U534L) 
was added to the slides and incubated for 15 minutes. Slides were then rinsed three times 
for 5 minutes each with TBS-T.  
The slides were then developed in DAB (MJS BioLynx Inc., Brockville, ON, Canada, 
Catalogue number: VECTSK4100), and care was taken not to keep the solution on for more 
than 5 minutes, as the colour change would happen within a minute. The DAB solution 
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was always made fresh and used immediately. The DAB solution was made in the 
following manner:  5 ml of dH2O, 2 drops (~84 l) of buffer, 4 drops (~100 l) of DAB 
and 2 drops (~80 l) H2O2 and mixed well prior to use.  
Next, the slides were placed in dH2O. Slides were then counterstained with 
haematoxylin (Leica Biosystems Inc., Concord, ON, Canada) for 1 minute and then place 
under tap water. Slides were then placed in 1% acid alcohol (HCl/70% Ethanol) and then 
washed in running tap water.  Slides were then stained blue in 2% ammonium 
hydroxide/70% ethanol and washed in water. 
Slides were then dehydrated in the following manner: 70% ethanol (1 minute); 95% 
ethanol x2 (1:1 minute); 100% ethanol x3 (1:1:1 minute); xylene x 2 (5:5 minutes) and then 
cleared and coverslips were placed using Cytoseal mounting medium (ThermoScientific, 
Runcorn Cheshire, WA, USA). 
3.3.4 Staining Controls 
A known high- and low-risk Straticyte control were included with each staining 
experiment. These controls were provided from Proteocyte AI Inc. (Toronto, Ontario, 
Canada). 
For an understanding on how Straticyte stratified lesions into risk groups see the 
section ‘Straticyte Risk Group Determination’ below.  
The histopathological images of the positive and negative, high and low-risk 
controls can be seen in Figure 3.1. 
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Figure 3.1. High- and low-risk S100A7 staining controls. High-risk controls (A (positive 
control) & B (negative control)) and low-risk controls (C (positive control) & D (negative 
control)). For both high and low-risk positive controls, staining was confined to the middle 
and upper layers of the epithelium.  
 
 
 
 
 
 
 
 
 
3.3.5 Specimen Analysis: Semi-Quantitative and Qualitative 
Following IHC, the specimens were analyzed under a light microscope using both 
semi-quantitative and qualitative measures. Cells staining positive for S100A7 were 
grossly counted throughout the epithelium of the entire specimen.  
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Table 3.7. Manual scoring based on the percentage of cells stained 
Score  Cells Stained 
0 zero 
1 1 - 20%  
2 21 - 40% 
3 41 - 60% 
4 61 - 80% 
5 81 - 100% 
 
Table 3.8. Manual scoring based on the intensity of staining 
Score Staining Intensity  
0 none 
1 mild 
2 moderate  
3 intense 
 
An intensity score was given to whichever intensity was most prevalent within the 
entire tissue specimen. These scores were combined to allow for a total score ranging from 
0 – 8, with 0 being the lowest score and 8 being the maximum score possible. Tissue level 
(ie. basal, parabasal, spinous or surface) of staining was also recorded and whether the 
staining was homogenous or focal was noted. Prior to initiating the evaluation, an oral 
histopathologist and the graduate student author scored 25 specimens together, to ensure 
consistency of methodology, and to avoid inter-and intra-observer bias. On two additional 
occasions, for quality assurance, the oral histopathologist and the graduate student author, 
rescored an additional 15 specimens each time to ensure consistent and accurate scoring. 
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Finally, upon completion of scoring all cases, 20 cases were chosen at random and scoring 
was evaluated by the oral histopathologist to ensure scoring calibration was maintained.  
Differences in score were < 1 for percentage of cell staining and < 1 for intensity of staining 
in all cases. Any discrepancy in scoring was then discussed between the oral 
histopathologist and the graduate student author and the agreed upon score was entered. A 
scoring difference of < 1 was deemed to be within an acceptable range to ensure cases were 
scored accurately using the semi-quantitative and qualitative method.  
 
3.3.6 Specimen Analysis: Quantitative Straticyte Assessment  
3.3.6.1 Image and Risk Analysis 
The S100A7-stained slides were digitally scanned at 20x magnification on a 
Hamamatsu Nanozoomer-XR slide scanner (Toronto Centre for Phenogenomics, Toronto, 
Canada). The digital images of the slides were imported into Visiopharm VIS (Hoersholm, 
Denmark). Using Visiopharm VIS, up to five 500 µm diameter region of interests (ROIs) 
were centered on areas with the highest S100A7 expression in the stratified mucosal 
epithelium and the S100A7 positivity (given as a percentage) and average cell size (total 
area of the ROIs / total number of identified nuclei) were calculated and used to generate 
the Straticyte-risk class and probability of cancer progression. The risk class and 
probability of cancer progression algorithm was generated using a clinical reference 
database of 150 unique cases (Proteocyte AI Inc., Toronto, Ontario).  
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3.3.6.2 Straticyte Risk Group Determination and Probability of 5-year Cancer 
Progression 
 
Selection cut-off was determined based on the two following rules: 
1. For all cases, a high cut-off was selected to differentiate the high-risk and non-high-
risk groups, with specificity >85% and P value of log rank test between high- and 
non-high-risk groups <0.05. 
2. For cases in the non-high-risk group, a low cut-off was selected to differentiate 
medium-risk and low-risk groups with sensitivity >90% and P value of log rank 
test between the medium- and low-risk groups <0.05. 
For both cut-offs, once the criteria were met, the cut-off that gave the best-balanced 
accuracy (average of sensitivity and specificity) was chosen [25, 129].  
The Nelson-Aalen-Breslow estimate, used to calculate the baseline cancer-free 
survival curve, was combined with the calculated risk scores from the 150 unique cases, to 
produce the expected 5-year cancer-free survival probability for a given case. Once this 5-
year cancer progression algorithm is calculated, a new case can be assessed a 5-year 
probability of cancer progression and assigned a low-, medium-, or high-risk [25, 129]. 
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Table 3.9. Straticyte risk group and associated probability of cancer progression 
over 5 years 
 Probability of Cancer progression Risk Group 
 60% High 
19%   and  60% Medium  
 19% Low 
Adapted from [25, 129] 
 
 
Figure 3.2. Straticyte Analysis Image. Regions of interest (ROIs) are outlined in 
dashed blue and two overlapping ROIs can be seen. Within the ROIs: red = S100A7-
negative cytoplasm; green = S100A7-negative nuclei; maroon = S100A7-positive 
cytoplasm and blue = S100A7-positive nuclei. Image provided by Dr. J. Hwang, 
Proteocyte AI, Toronto, ON, Canada. 
 
Only segmented pixels from inside of the ROIs are used for final calculation of S100A7 
positivity and average cell size [25, 129]. 
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3.3.6.3 Total Epithelium Assessment 
For total epithelium assessment, the entire epithelium from the surface to the basement 
membrane was manually annotated as the ROIs and the S100A7-positive area, S100A7-
negative area, and the total area of the ROIs were analyzed and used to calculate the 
percentages of S100A7-positive and -negative areas. Lesions diagnosed as carcinoma were 
omitted from the total epithelium assessment as in many instances, the epithelium was 
difficult to clearly identify for manual annotation of ROIs. 
Figure 3.3. Measure of total area of S100A7 staining within entire epithelium. The 
ROI are outlined in dashed green and within the ROI: blue = S100A7-negative pixels and 
green = S100A7-positive pixels. Image provided by Dr. J. Hwang, Proteocyte AI, 
Toronto, ON, Canada. 
 
[25, 129].  
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3.4 -catenin Staining and Evaluation  
3.4.1 Specimen Preparation and -catenin Staining 
Monoclonal mouse anti-human -catenin (code No. IR702) was obtained from 
DAKO (Glostrup, Denmark). Automated staining at University Hospital, London, ON, 
Canada, was performed according to the manufacturer’s instructions. 
Tissue specimens were cut into sections of approximately 4 m. Pre-treatment with 
heat-induced epitope retrieval (HIER) was performed using Dako PT Link. The tissues 
were pretreated using EnVision FLEX Target Retrieval Solution, High pH (50x) (Code 
K8004).  
Pre-treatment of formalin-fixed, paraffin-embedded tissue sections was performed 
using the 3-in-1 specimen preparation procedure for Dako PT Link. Following staining, 
the sections were dehydrated, cleared and mounted.  
The staining steps and incubation times were pre-programmed into the Autostainer 
Link software. The visualization system was EnVision FLEX, High pH (Link) (Code 
K8000). Reagents were applied in a volume 1 x 200 L per slide. All incubation steps were 
performed at room temperature. Counterstaining was performed in hematoxylin using 
EnVision FLEX Hematoxylin (Link) (Code K8008). Positive and negative control tissues 
as well as negative control reagent were run simultaneously using the same protocol as the 
case specimens. The negative control reagent was FLEX Negative Control, Mouse (Link) 
(Code IR750). 
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3.4.2 -catenin Evaluation 
A qualitative assessment was used to evaluate the staining of -catenin. 
3.4.3 -catenin Control 
Figure 3.4. -catenin control from gastrointestinal tissue (GIT). Original magnification 
x200. Positive staining (brown) is seen within the cytoplasm and cytoplasmic membrane 
of the epithelial tissue.  
 
 
3.5 Cyclin D1 Staining and Evaluation  
3.5.1 Specimen Preparation and Cyclin D1 Staining 
Monoclonal rabbit anti-human Cyclin D1 (code No. IR083) was obtained from the 
manufacturer, DAKO. Automated staining was performed at University Hospital, London, 
ON, Canada. 
Tissue specimens were cut into sections of approximately 4 m. Pre-treatment with 
heat-induced epitope retrieval (HIER) was performed using Dako PT Link. Tissues were 
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pretreated using EnVision FLEX Target Retrieval Solution, High pH (50x) (Code K8004) 
for 20 minutes at 97°C followed by 5 minutes in EnVision FLEX Wash Buffer (20x) (Code 
K8007). 
The visualization system was EnVision FLEX, High pH (Link) (Code K8000). The 
staining steps and incubation times were pre-programmed into the Autostainer Link 
software. The reagent application volume was 1 x 200 L per slide. All incubation steps 
were performed at room temperature. 
Counterstaining in hematoxylin was done using EnVision FLEX Hematoxylin 
(Link) (Code K8008). After staining, the sections were dehydrated, cleared and mounted. 
Positive and negative control tissues as well as negative control reagent were run 
simultaneously using the same protocol as the case specimens. The negative control reagent 
was FLEX Negative Control, Rabbit (Link) (Code IR600). 
3.5.2 Cyclin D1 Evaluation 
A qualitative assessment was used to evaluate the staining of cyclin D1. 
 
 
 
 
 
 
 
56 
3.5.3 Cyclin D1 Control 
Figure 3.5. Cyclin D1 control from lymphoid tissue. Original magnification x200. 
Positive staining (brown) is seen within the nucleus.  
 
 
3.6 Statistical Analysis 
Statistical Analysis was performed using Instat GraphPad Prism 8 (GraphPad 
Software, San Diego, CA, USA). The level of significance was set at P < 0.05.  
To compare progressing, non-progressing and control cases for manual and 
automated (Straticyte) scoring methods, both a Kruskal-Wallis test and a Brown-
Forsythe ANOVA test were utilized. A Mann-Whitney test and a Welch’s T test were 
performed to compare both progressing to non-progressing cases and progressing to control 
cases.  
To identify which scoring method had the best ability to predict disease progression, 
a binary logistic regression model was used to compare non-progressing to control cases 
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and non-progressing to progressing cases. A Pearson Correlation Coefficient was used to 
asses for correlation between variables for the entire data set. A Pearson Correlation 
Coefficient was also used to identify variable correlation when comparing control to non-
progressing cases and non-progressing to progressing cases.   
Step-wise regression utilizing a method called ‘forward-backward selection’ to find 
the most parsimonious model without losing predictive power was then used to identify 
the variables most predictive of control vs. non-progressing outcomes and non-progressing 
vs. progressing outcomes. This was presented as odds ratio with 95% confidence intervals. 
Variance inflation factors were evaluated to assess for multicollinearity, a measure 
to ensure that the input variables are not unduly influencing one another, making it difficult 
to evaluate the dependent variable or outcome [130].   
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Chapter 4 
4.0 Results 
4.1 Anatomic Location 
In Tables 4.1, 4.2 and 4.3 are the distribution of the anatomic locations for the 
progressive, non-progressive and control/hyperkeratosis cases: 
Table 4.1. Location category of initial biopsy for progressing cases 
Location Cases 
FOM/Ventral 
Tongue 14 
Soft Palate 0 
Lateral Tongue 15* 
Gingiva 0 
Retromolar Pad 0 
Buccal Mucosa 1 
Lower Lip 0 
Dorsal Tongue 0 
*Initial biopsy of Case #27 had two specimens 
 
Table 4.2. Location category of initial biopsy for non-progressing cases 
Location Cases 
FOM/Ventral 
Tongue 3 
Soft Palate 3 
Lateral Tongue 11* 
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Gingiva 0 
Retromolar Pad 1 
Buccal Mucosa 0 
Lower Lip 0 
Dorsal Tongue 0 
*Initial biopsy of Case #14 had two specimens 
 
Table 4.3. Location category of initial biopsy for control/hyperkeratosis/normal 
cases 
Location Cases 
FOM/Ventral 
Tongue 5 
Soft Palate 1 
Lateral Tongue 11 
Gingiva 4 
Retromolar Pad 3 
Buccal Mucosa 0 
Lower Lip 0 
Dorsal Tongue 1 
 
For progressing cases, most of the biopsies came from the lateral tongue and ventral 
tongue/FOM. For non-progressing and control cases, the lateral tongue was the most 
common anatomical site. 
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4.2 Diagnosis 
Table 4.4. Diagnosis category of initial biopsy for progressing cases 
Diagnosis Cases 
Other/Normal  3 (10%) 
Mild Dysplasia*, ** 12 (40%) 
Moderate Dysplasia 10 (33%) 
Severe Dysplasia 5 (17%) 
*Included one case of verrucous hyperplasia with early verrucous carcinoma as 
this is considered a low-grade lesion 
**Initial biopsy of Case #27 had two specimens 
 
Table 4.5. Diagnosis category of initial biopsy for non-progressing cases 
Diagnosis Cases 
Other/Normal * 3 (17%) 
Mild Dysplasia 8 (44%) 
Moderate Dysplasia 3 (17%) 
Severe Dysplasia 4 (22%) 
*Initial biopsy of Case #14 had two specimens 
 
Table 4.6. Diagnosis category for initial biopsy of control/hyperkeratosis/normal 
cases 
Diagnosis Cases 
Other/Normal  25 (100%) 
Mild Dysplasia 0 (0%) 
Moderate Dysplasia 0 (0%) 
Severe Dysplasia 0 (0%) 
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 The most common diagnosis for progressing and non-progressing cases was mild 
dysplasia. The controls were all normal tissue/hyperkeratosis.  
4.3 Age of Subjects  
 
Figure 4.1.  Median age at the time of initial biopsy. Statistical comparison using 
Kruskal-Wallis test (p = 0.10). *p < 0.05; **p < 0.01 
 
 
Although not statistically significant (p = 0.10), progressing cases had a higher 
age at time of initial biopsy relative to non-progressing and control cases. Median age for 
the progressing, non-progressing and control groups was 59.1 years, 57.6 years and 50.4 
years respectively.  
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4.4 Sex of Subjects  
Figure 4.2. Sex of subjects for progressing cases 
 
 
 
Figure 4.3. Sex of subjects for non-progressing cases 
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Figure 4.4. Sex of subjects for controls/hyperkeratosis/normal 
 
 
 The predominant sex for progressing cases was male. Sex was more evenly 
distributed for the non-progressing and control groups.  
 
4.5 Additional Demographic & Risk Factor Data 
From the census sent out to the referring surgeons, the response rate was 18/27 = 
67% and did not allow for any useful statistics to be obtained. The reasons for surgeon’s 
lack of participation in the study included: unwilling (1), deceased (1), retired (3), 
unknown/did not reply (4). In addition to this, all the initial pathology reports were 
evaluated to determine if the biopsies were incisional or excisional and due to the small 
number of reports that provided this information, it was determined not to include this 
information in the study. The results from this census are provided in Table 4.7. 
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Table 4.7. Additional demographics & risk factor data from referring surgeon  
Subject # Sex Location Alcohol Tobacco 
Localized/
Diffuse Alive 
Still following/last 
evaluated Still persisting 
1 M FOM Yes Yes Localized 
 
October 2013 No 
2 F Soft palate 
      
3 F FOM No No Diffuse Yes Yes 
 
4 F FOM No 
 
Diffuse 
 
March 2013 
 
5 M 
Lateral 
tongue No No Diffuse 
 
2010 
 
6 F 
Ventral 
tongue No No Localized Yes Yes 
 
7 M 
Lateral 
tongue 
      
8 M 
Lateral 
tongue Yes Yes Diffuse 
No (Lung 
Cancer) 
  
9 F 
Lateral 
tongue No No Localized Yes Yes 
 
10 M FOM 
      
11 M FOM 
      
12 M 
Lateral 
tongue No No Localized Yes October 2007 
 
13 F Soft Palate No No Localized Yes Yes 
 
14 F 
Lateral 
tongue No No Localized Yes Yes 
 
15 M 
Lateral 
tongue 
      
16 M 
Lateral 
tongue 
      
17 F 
Retromolar 
pad 
      
18 F 
Ventral 
tongue No Yes Localized Yes Yes No 
19 M 
Lateral 
tongue No No Localized Yes September 2012 
 
20 M 
Lateral 
tongue 
      
21 M 
Lateral 
tongue Yes Yes Localized Yes April 2015 No 
22 M 
Lateral 
tongue 
 
Yes Localized 
 
September 2011 
 
 
 
65 
23 M 
Buccal 
mucosa 
      
24 M Lower lip No No Diffuse Yes Yes 
 
25 F 
Lateral 
tongue No No Localized Yes February 2017 SCC in 2015; nothing since 
26 F 
Lateral 
tongue Yes Yes Localized Yes 2015 No 
27 F 
Lateral 
tongue No No Localized No (MI) 
  
 
 
4.6  Straticyte risk group for progressing, non-progressing & control cases 
Table 4.8. Straticyte risk group for initial biopsy of progressing cases  
Straticyte Risk 
Group Cases 
Low 9 (30%) 
Medium 20* (67%) 
High 1 (3%) 
*Case 27 had two initial biopsy specimens 
 
 
Table 4.9. Straticyte risk group for initial biopsy of non-progressing cases 
Straticyte 
Risk Group Cases 
Low 4 (22%) 
Medium 
12* 
(67%) 
High 2 (11%) 
*Case 14 had two initial biopsy specimens 
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Table 4.10. Straticyte risk group for initial biopsy of 
controls/normal/hyperkeratosis cases 
Straticyte 
Risk Group Cases 
Low 6 (24%) 
Medium 18 (72%) 
High 1 (4%) 
 
Medium risk was the most common risk group amongst progressing, non-progressing and 
control groups.  
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4.7 Immunohistochemistry (IHC) 
4.7.1 S100A7  
Figure 4.5. Illustrative S100A7 cytoplasmic and nuclear staining (brown). Case #2 of 
progressing group. Diagnosis = mild to moderate dysplasia; manual score = 4 (cell 
score = 2; intensity score = 2); Straticyte score = 32.03). A = original magnification 
x50; B = original magnification x100; C = original magnification x200 
 
 
 
 
 
 
 
     
  
 
 
 
 
 
 
A) B) 
C) 
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Figure 4.6. Illustrative S100A7 staining for initial biopsy of Case #28: Diagnosis = 
mucositis with hyperorthokeratosis; manual score = 6 (cell score = 4; intensity score 
= 2); Straticyte score = 26.48). Staining confined to upper layers of epithelium 
with sparing of the basal and parabasal layers. A = original magnification x50; B = 
original magnification x100; C = original magnification x200 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B) A) 
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Figure 4.7. Illustrative S100A7 staining for subsequent biopsy of Case #28: 
Diagnosis = moderate to severe dysplasia; manual score = 6 (cell score = 3; intensity 
score = 3); Straticyte score =18.02). Staining present in both the cytoplasm and 
nucleus. A = original magnification x100; B = original magnification x200 
 
 
 
4.7.1.1 Qualitative Evaluation of S100A7 Staining 
S100A7 immunoreactivity was present in both the cytoplasm and the nucleus 
although more prominent in the cytoplasm. Staining was limited to the middle and 
superficial layers of the epithelium. Staining was not evident in the basal layer. Intensity 
of staining was variable.  
 
 
 
 
 
 
 
A) B) 
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4.7.2 Cyclin D1  
 
Figure 4.8. Illustrative Cyclin D1 staining. Case #15 of lateral tongue. Diagnosis = 
moderate dysplasia. Staining confined to nucleus of basal and parabasal layer. A = 
original magnification x50; B = original magnification x200. 
 
 
 
4.7.2.1 Qualitative Evaluation of cyclin D1 Staining 
Cyclin D1 staining was isolated to the basal and parabasal layers and was most 
prominent in the parabasal layer. Staining occurred in both the nuclei and the cytoplasm, 
with nuclei staining being most prominent. There was no identifiable difference on cyclin 
D1 staining with any of the various grades of dysplasia and quantitative evaluation was 
not performed.  
 
 
 
 
A) B) 
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4.7.3 -catenin  
 
Figure 4.9. Illustrative -catenin staining. Case #15 of lateral tongue. Diagnosis = 
moderate dysplasia. Staining occurring in the cytoplasm and cytoplasmic membrane 
in basal and parabasal layers and cytoplasmic membrane in layers higher up in the 
epithelium. A = original magnification x50; B = original magnification x200.  
 
 
  
4.7.3.1 Qualitative Evaluation of -catenin Staining 
-catenin staining was most prominent in the basal and parabasal layer of the 
epithelium. At all levels of the epithelium, -catenin stained the outer cell membranes. At 
the basal and parabasal levels, -catenin was also present in the cytoplasm, but cytoplasmic 
staining was not evident at levels beyond the parabasal layer. No significant staining was 
identified in the nucleus. -catenin staining did not show any difference between various 
grades of dysplasia and as such, quantitative analysis could not be performed. 
 
A) B) 
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4.8 Statistical Analysis 
4.8.1 Initial Biopsy Score Evaluation   
4.8.1.1 Manual Scoring Method 
Figure 4.10. Total manual score for initial biopsy of progressing, non-progressing 
and hyperkeratosis/normal/control cases. Statistical comparison using Kruskal-
Wallis Test (p = 0.01) and by Brown-Forsythe ANOVA Test (p = 0.01). *p < 0.05; 
**p < 0.01 
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Figure 4.11. Total manual score for initial biopsy of progressing and non-
progressing cases. Statistical comparison using Mann-Whitney Test (p = 0.69) and 
Welch’s T Test (p = 0.85). *p < 0.05; **p < 0.01 
 
 
Figure 4.12. Total manual score for initial biopsy of progressing and control cases. 
Statistical comparison using Mann-Whitney Test (p = 0.004) and Welch’s T Test (p 
= 0.004). *p < 0.05; **p < 0.01 
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Comparing all three groups (progressing, non-progressing and control) and 
comparing progressing to control cases using the manual scoring method achieved a 
statistically significant result with P = 0.01 and P = 0.004, respectively. However, 
comparison of progressing and non-progressing cases using the manual scoring method did 
not achieve a statistically significant result.  
 
4.8.1.2 Automated (Straticyte) Scoring Method 
 
Figure 4.13. Automated (Straticyte) score for initial biopsy of progressing, non-
progressing and hyperkeratosis/normal/control cases. Statistical comparison using 
Kruskal-Wallis Test (p = 0.24) and by Brown-Forsythe ANOVA Test (p = 0.18). *p 
< 0.05; **p < 0.01 
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Figure 4.14. Automated (Straticyte) score for initial biopsy of progressing and 
non-progressing cases. Statistical comparison using Mann-Whitney Test (p = 0.10) 
and Welch’s T Test (p = 0.09). *p < 0.05; **p < 0.01 
 
 
 
Figure 4.15. Automated (Straticyte) score for initial biopsy of progressing and 
control cases. Statistical comparison using Mann-Whitney Test (p = 0.33) and 
Welch’s T Test (p = 0.25). *p < 0.05; **p < 0.01 
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Comparison of all three groups (progressing, non-progressing and controls) using 
Straticyte did not achieve a statistically significant result. Neither did comparison of 
progressing to non-progressing cases or progressing to control cases.  
 
4.8.2 Binary Scoring  
Tables 4.11 and 4.12 are WHO binary scoring for the initial biopsy of the progressing 
and non-progressing cases. Scoring was performed by an experienced oral 
histopatholgist.  
 
Table 4.11. WHO binary scoring of initial biopsy for progressing cases shown as 
both the number and percentage (%) of cases.  
High Grade Low Grade 
19 (73.1%)  7 (26.9%) 
 
Table 4.12. WHO binary scoring of initial biopsy for non-progressing cases shown 
as both the number and percentage (%) of cases.  
High Grade Low Grade 
7 (46.7%) 8 (53.3%) 
 
Comparing progressing to non-progressing cases using the binary scoring system 
resulted in progressing cases having a greater percentage (73.1% vs 46.7%) of high-grade 
lesions and non-progressing cases having a greater percentage (53.3% vs 26.9%) of low-
grade lesions.  
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Table 4.13. Inter-rater reproducibility using WHO binary score system for the 
initial biopsy of progressing cases. Scoring was performed by an experienced oral 
histopathologist and the graduate student author.  
Same scoring Different scoring 
19 (73.1%) 7 (26.9%) 
 
 
Table 4.14. Inter-rater reproducibility using WHO binary score system for the 
initial biopsy of non-progressing cases. Scoring was performed by an experienced 
oral histopathologist and the graduate student author.  
Same scoring Different scoring 
14 (93.3%) 1 (6.7%) 
 
 
Inter-rater reproducibility using the binary scoring system resulted in a high 
percentage of same score designation between the experienced oral histopathologist and 
the graduate student author for both progressing (73.1%) and non-progressing (93.3%) 
cases.  
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4.8.3 Correlation Analysis 
4.8.3.1 Evaluation of Entire Dataset 
Figure 4.16. Pearson’s Correlation Coefficient of Variables used for S100A7 
evaluation of all cases in the study. Brown/red squares indicated a positive 
association/correlation and blue/purple squares indicate a negative 
association/correlation.  
 
There is a strong linear correlation observed between: 1) Straticyte risk group and 
automatic scoring; 2) manual scoring and area stained. There was a moderately positive 
correlation between the automatic and manual scoring methods.  
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Figure 4.17. Distribution of variables for initial biopsy of entire dataset. 
 
 
Sex was well distributed with a slight tendency towards males. There were almost 
two times as many progressing cases as there were non-progressing cases. The most 
common diagnosis was mild dysplasia (not including control cases which were primarily 
hyperkeratosis). The most common location was the lateral tongue followed by the 
FOM/ventral tongue. Most subjects fell between the age of 50 – 75 years old and most 
specimen had a Straticyte risk of medium.  
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4.8.3.2 Control vs. Non-Progressing Cases 
A binary logistic regression model was applied to compare controls to non-
progressing cases using all the same previously described variables as covariates. The 
response is whether the individual is healthy (control) or if the individual has a non-
progressing lesion. Table 4.15. is a summary of the modelled output. 
Table 4.15. Binary logistics regression of control vs. non-progressing lesions 
 
 
It appears that the only statistically significant value in this model is the manual 
scoring, as it provided a p-value closest to 0.05.  
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Figure 4.18. Pearson Correlation Coefficient for controls vs. non-progressing cases. 
Brown/red squares indicated a positive association/correlation and blue/purple squares 
indicate a negative association/correlation. 
 
 
There is no strong connection between the automatic and the manual scoring 
methods.  
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Figure 4.19. Variance inflation factors for controls vs. non-progressing cases 
showing there is no strong multicollinearity 
 
 
Figure 4.19 shows variance inflation factors for the variables. It is a measure of 
multicollinearity (ie. how close are different variables to being linear combinations of one 
another?). Values below 10 are considered reasonably dissimilar to one another and 
considered not to have multicollinearity. Multicollinearity creates a problem because it 
suggests input variables are influencing one another making it difficult to test how much 
the combination of the independent variables affect the dependent variable or outcome 
[130]. 
We do not see a strong variance inflation from either of the scoring methods, 
suggesting no significant multicollinearity is present, thus giving us confidence in our 
results and conclusions.  
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Table 4.16 is a step-wise regression method called forward-backward selection and it picks 
the most parsimonious model without losing prediction power. The final model ended up 
using only the Age and Manual Scoring selection variables.  
Table 4.16. Step-wise regression analysis of controls vs. non-progressing cases 
 
 
Based on this regression model, manual scoring was found to be highly significant. 
Age, while not being individually significant, may have an impact on the result when paired 
with manual scoring.  
 
Table 4.17. Odds ratio contributions for each variable in the final model along with 
95% confidence intervals 
 
The odds ratio is defined as: 
 
Therefore, a 1-point increase in the manual scoring variable equates to an increase 
in the odds ratio by 1.88, indicating a higher probability that the patient will have a non-
progressing lesion. 
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4.8.3.3 Non-progressing vs. Progressing Cases 
Once again, a binary logistic regression model was applied to compare non-
progressing to progressing cases using all the same previously described variables as 
covariates. The response is whether the individual has a non-progressing or a progressing 
lesion. Table 4.18 is a summary of the modelled output.  
 
Table 4.18. Binary logistic regression for non-progressing vs progressing cases 
 
Only the automatic (Straticyte) scoring method approaches significance (P = 0.092) to 
the response in the presence of the other variables.  
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Figure 4.20. Pearson correlation coefficient for non-progressing vs. progressing 
cases. Brown/red squares indicated a positive association/correlation and blue/purple 
squares indicate a negative association/correlation. 
 
 
Figure 4.20 suggests there is no strong connection between the automatic and 
manual scoring methods.  
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Figure 4.21. Variance inflation factors for non-progressing vs. progressing cases 
showing there is no strong multicollinearity. 
 
 
 
Table 4.19 shows the variable selection using a step-wise regression method called 
forward-backward selection and it picks the most parsimonious model without losing 
prediction power to determine which variables are the best predictors of progressing and 
non-progressing cases 
Table 4.19. Step-wise regression for non-progressing vs. progressing cases 
 
 
Automatic scoring had some significance on its own suggesting that it is the best 
predictor of progression likelihood, however, there is only weak evidence (t-test p-value is 
0.078). The manual scoring method did not have a strong predictive value.  
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Table 4.20. Odds ratio and 95% confidence interval for non-progressing vs. 
progressing cases 
 
 
A single point of increase in the automatic scoring variable leads to about a single point 
increase in the odds ratio.  
 
In this case, the odds ratio is defined as: 
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Chapter 5 
5.0 Discussion  
5.1 Anatomic Location 
For progressing cases, most of the biopsies came from the lateral tongue and ventral 
tongue/FOM. The lateral tongue and ventral tongue/FOM are considered high risk sites for 
oral cancer [57, 58]. It was interesting that for the progressing group, the lateral tongue and 
ventral tongue/FOM were almost the exclusive anatomic sites, further supporting the 
notion that these are high risk sites.  
For non-progressing and control cases, the lateral tongue was the most common 
anatomical site.  Although other anatomic sites were also represented, the lateral tongue 
and ventral tongue/FOM were still the most common anatomic sites, suggesting that these 
tend to be the most common sites for leukoplakia in general.  
 
5.2 Age 
Progressing cases had a higher age at time of initial biopsy relative to non-
progressing and control cases. This is consistent with the literature where advanced age has 
been shown to be a risk factor for cancer development [58, 62].  
5.3 Sex 
There was a slight trend towards progressing lesions being identified in males. 
There was almost equal sex distribution for non-progressing and control cases. The 
literature suggests that oral potentially malignant lesions are more common in males, 
however, rates of transformation tend to be higher in females and the reasons for this are 
not completely understood [12, 13]. Our study did not specifically evaluate transformation 
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to malignancy so we were not able to compare this outcome to what has been seen 
previously in the literature in terms of sex predilection.  
5.4 Biomarkers  
5.4.1 S100A7  
 Prior work with S100A7 has shown it to be a potentially useful biomarker in 
predicting a poor outcome in head and neck carcinoma [107] and as a risk factor for 
transformation from oral dysplasia to carcinoma [108]. Hwang et al. have also tested the 
predictive value of S100A7 [25].  
We hypothesized that S100A7 would have higher levels in potentially malignant 
lesions that underwent progression compared to lesions that did not progress. In this study, 
S100A7 staining was present in all three groups: progressing, non-progressing and control 
(normal tissue). The findings of this study did not show that S100A7 was overexpressed in 
progressing lesions compared to non-progressing lesions, but rather, S100A7 expression 
was similar between the two groups. S100A7 expression was evaluated using both manual 
and automated scoring methods and neither method showed that S100A7 expression was 
significantly higher in the progressing lesions compared to non-progressing lesions. This 
finding suggests that more work is needed to determine if S100A7 is a useful predictor for 
progression of potentially malignant oral lesions and in further understanding the role of 
S100A7 in tumour development and progression.  
S100A7 is known to have many physiologic functions such as chemotaxis for 
inflammatory mediators [82-84], matrix remodelling and angiogenesis [103]. In all cases, 
S100A7 expression was mostly limited to the middle and upper layers of the epidermis, 
with the basal and parabasal layers being spared. This is common to what has been 
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described previously in psoriatic patients [92].  By being expressed only in the upper layers 
of the epidermis, S100A7 only begins to be expressed as the epithelial cells mature and 
move closer towards the surface suggesting that S100A7 is induced in 
differentiated/differentiating cells.  
 S100A7 has also been speculated to have a protective function against invasion 
[100]. Differential expression of S100A7 mRNA has been seen in DCIS compared with 
invasive breast cancers; in which S100A7 is overexpressed in DCIS and minimally 
expressed in invasive breast cancers [98]. A study evaluating S100A7 expression in 
traumatic fibromas and normal tissue has revealed S100A7 to be over 10-fold higher in 
traumatic fibromas than that of normal tissue, prompting the authors to suggest a protective 
function for S100A7 against invasion, as traumatic fibromas grow in size but rarely 
transform to malignancy or invade [131]. A study by Probstmeier et al. that evaluated the 
expression of four different S100 proteins in healthy gingiva, traumatic fibromas, 
leukoplakia and OSCC, found increased expression of S100A7 in traumatic fibromas, 
leukoplakia and OSCC relative to healthy controls, with all being statistically significant 
[132], however, this study did not mention if it was evaluating poorly or well differentiated 
OSCC.  
In keratinocyte cell lines, S100A7 expression has been shown to be higher in CIS 
and differentiated SCC, than it is in undifferentiated SCC, further supporting that S100A7 
may have a protective role [95]. Another study found S100A7 to be highly expressed in 
pre-invasive and early staged, well-differentiated OSCC but minimal or no expression of 
S100A7 was found in late staged, undifferentiated and invasive OSCC [94]. A prospective 
study evaluating S100A7 expression levels in OSCC would help to further improve our 
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understanding of S100A7 and its potential protective role against tumour progression and 
invasive malignancy.  
 Pre-malignant and malignant lesion progression has been shown to be related to 
accumulated genetic alteration [20, 21, 33, 34]. Risk factors such as alcohol and tobacco 
are some of the main causes of genetic alteration leading to OSCC [34]. It would be useful 
to determine the relationship between tobacco and alcohol consumption to the expression 
of S100A7. If S100A7 has a protective role for tumour progression, it would be anticipated 
that alcohol and tobacco consumption may be associated with decreased expression of 
S100A7. Unfortunately, in this study we did not evaluate the correlation of known risk 
factors with progressing and non-progressing lesion groups or the expression of S100A7. 
The reason for this was an inability to obtain sufficient demographic and risk factor data 
from the referring clinicians. A future study looking at the relationship between alcohol 
and tobacco consumption and S100A7 expression would be useful in further understanding 
the protein biomarkers role.  
 
5.4.2 Cyclin D1 
 Cyclin D1 is a known cell cycle regulator and has been linked to many oncogenic 
functions [116, 119]. In this study, cyclin D1 was expressed primarily in the basal and 
parabasal layers of all oral dysplastic lesions. There was no differential staining in the 
various grades of dysplasia and cyclin D1 did not appear to be a useful marker in predicting 
progression of oral dysplastic lesions.  
 Another study found cyclin D1 to be expressed in OSCC, however, in oral dysplasia 
it was cyclin E, rather than cyclin D1 that was expressed [122]. This could be one 
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explanation for not noticing a difference in the pre-malignant phase and perhaps cyclin E 
would be a more useful marker for predicting pre-malignant progression.  
 Another study found similar expression of cyclin D1 in oral epithelial dysplasia and 
OSCC [121]. These authors also observed that approximately 10% of normal epithelium 
expresses cyclin D1. Other studies have also shown that cyclin D1 nuclear staining in 
normal skin tissue will range between 5-40% of cells [133]. Rousseau et al. also observed 
that staining in normal tissue is often confined to the basal and parabasal layers but can be 
seen higher up in the epithelium in dysplasia. This was not observed in our study as staining 
was only observed in basal and parabasal layers in both normal and dysplastic lesions.  
 To our knowledge, there have been no studies comparing the direct relationship 
between S100A7 and cyclin D1. Because there was no observed differential staining for 
any of the potentially premalignant oral lesions in this study we did not evaluate the 
expression of S100A7 and cyclin D1 simultaneously in each of our samples to determine 
if a relationship exists.  
 As S100A7 has been suggested to have a protective function against tumour 
progression and invasiveness [94], and overexpression of cyclin D1 has been associated 
with advanced clinical disease and a worse prognosis in both laryngeal [120] and OSCC 
[116, 134], evaluating the expression of S100A7 and cyclin D1 at varying stages of OSCC 
might be useful to determine if there is a reciprocal relationship, as has been suggesting 
between S100A7 and -catenin [94].   
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5.4.3 -catenin 
 -catenin plays a central role in the Wnt cascade. In the absence of Wnt signalling, 
-catenin is targeted for proteolytic degradation, however, in the presence of Wnt protein,  
-catenin avoids degradation, and its levels increase in the cytoplasm, eventually leading 
to its transport to the nucleus where it is involved with transcription of Wnt-regulated genes, 
some of which may be involved in cancer development and progression [110, 112, 113].  
The -catenin-cadherin complex is important for cell adhesion and fulfills a 
protective role against invasion and spread. Loss of the -catenin-cadherin complex is 
considered to be a late event in tumourigenesis as its loss has been observed with invasion, 
metastasis and loss of differentiation [114].  
S100A7 and -catenin are believed to have a reciprocal effect on one another such 
that S100A7 can target -catenin for degradation via a non-canonical mechanism and that 
downregulation of S100A7, increases -catenin signalling leading to promotion of tumour 
growth and progression [94].  
In the present study, -catenin expression was present in the cytoplasmic membrane 
at all levels of the epithelium. It was also present in the cytoplasm of the basal and parabasal 
layers only. In neoplastic processes, -catenin expression is shown diffusely through the 
cytoplasm and within the nucleus [135]. As this study only evaluated potentially pre-
malignant oral lesions,  -catenin was not expected to stain the nucleus and cytoplasm 
diffusely and it did not. 
A follow up study that prospectively evaluated -catenin and S100A7 levels in 
individuals with differentiated, early OSCC and in individuals with undifferentiated, 
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advanced OSCC may further help to explain the relationship between S100A7 and -
catenin.  
   
5.5 Comparison of Automated (Straticyte) and Manual Scoring Methods 
In evaluating the utility of predicting progression of oral epithelial dysplasia, 
neither the automated (Straticyte) or the manual scoring methods proved to be superior 
to one another. Evaluation of the initial biopsies for progressing, non-progressing and 
control cases, showed the manual scoring method to be better at predicting progression 
than the automated method, and this result was statistically significant when analyzed using 
Brown-Forsythe and Kruskal-Wallis tests (P=0.01). However, when this result was 
analyzed more closely, the manual scoring method was useful for differentiating the 
progressing and control groups (P=0.004), but not the progressing and non-progressing 
groups.  
Further evaluation, using the binary logistics regression model with step-wise 
regression, although not statistically significant (P=0.08), showed the automated scoring 
method was better at predicting progression of oral dysplasia than the manual scoring 
method.  
Due to the variability in results, it is difficult to conclude that either the manual or 
automated (Straticyte) method were superior to the other.  
One explanation for this is that Straticyte was designed to predict progression of 
dysplasia to malignancy and this study was evaluating the utility of Straticyte in 
predicting progression of oral dysplasia alone. It could be possible that the algorithms 
Straticyte uses to predict progression to malignancy are not useful or sensitive enough to 
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predict progression of dysplasia alone; to our knowledge, this has not been evaluated 
previously. As the development of OSCC is believed to proceed in a stepwise fashion 
through increasing degrees of oral dysplasia [19], we felt that in being able to predict which 
oral dysplastic lesions will progress, this would ultimately assist with cancer prevention 
and was one of the rationales for doing this study. 
When comparing non-progressing and control cases using binary logistics 
regression, the manual scoring method appeared to be superior to the automated method 
and this result was statistically significant (P=0.016). This suggests that S100A7 
expression as evaluated through the manual scoring method was useful at differentiating 
healthy controls from non-progressing oral dysplastic lesions.   
Analysis of the entire dataset showed a strong linear correlation between the manual 
scoring method and the computer evaluation of ‘the area stained’ with S100A7. The 
manual scoring method and ‘the area stained’ having a strong correlation is important 
because one of the variables of the manual scoring method was the percentage of cells 
stained. The percentage of cells stained was estimated by an experienced oral 
histopathologist and the graduate student author for each sample. The computer evaluation 
of the epithelial area stained with S100A7 and the manual scoring method were positively 
correlated. This suggests that percentage of cells stained as evaluated by the oral 
pathologist and the graduate student was similar to the area calculated by the computer.  
There was also a moderately positive correlation between the automatic and manual 
scoring methods when analyzed using Pearson Correlation Coefficient, suggesting that 
both methods were evaluating the same thing.  
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5.6 Binary Scoring System  
At the moment, there is no biomarker that has proven to be consistently superior to 
histopathological diagnosis in predicting progression of oral dysplasia or transformation to 
malignancy. Therefore, evaluation of oral dysplastic lesions by two experienced oral 
histopathologists, using a binary system for diagnosis, with well-defined criteria, into low- 
and high-risk lesions, may still be the most objective method.  Although the results of a 
binary system in predicting transformation to malignancy have been mixed, the inter-rater 
reproducibility and agreement has previously been shown to be improved [22, 71, 72]. 
Evaluation of the utility of the binary scoring system in our study produced inter-rater 
reproducibility of 73.1% and 93.3% for progressing and non-progressing cases, 
respectively.  
Utilizing a binary system may mean that overall, fewer lesions are excised, as the 
binary system will divide the moderate dysplasia group into low- and high-risk lesions. 
Currently, in most clinical practice, moderate dysplasia would be excised. If a binary 
system is utilized, clinicians will need to be vigilant with low-risk lesions and not ignore 
them, assuming they are harmless. Some studies have shown that the malignant 
transformation rate of the low-risk group can be as high as 15% [71]. 
A binary system has been shown previously to accurately differentiate the moderate 
dysplasia group into low- and high-risk lesions and be a useful tool for predicting 
progression [71]. However, a follow-up study showed the binary system improved inter-
rater reliability but failed to accurately differentiate the ‘moderate dysplasia’ group [72].  
It needs to be mentioned that the binary system still has some element of subjectivity. 
Although there are specific cytological and architectural criteria that need to be identified, 
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there is no specific guideline on how many elements are required to consider the criteria 
positive. This could be one potential reason that binary system results are not always 
replicated between studies.  
 
5.7 Limitations of the Study 
For both the manual and automated scoring methods, a component of the score was 
based on the number of cells staining positive with S100A7. Straticyte evaluation utilized 
‘regions of interest (ROI)’ whereas the manual scoring method evaluated the entire tissue 
specimen. This could have led to some difference in the scoring between the two methods. 
The ROIs Straticyte uses are 500 m diameter circles centered on staining ‘hotspots’. 
This allows Straticyte to focus its analysis at specific areas of a tissue biopsy but does 
not necessarily provide a global evaluation of the entire tissue sample.  
One reason for scoring the lesions as we did with the manual method is because of 
the field effect, which as discussed in Chapter 1, suggests that a field of tissue surrounding 
the lesions of interest will be subject to genetic changes [27, 29]. In following this principle, 
by evaluating the whole tissue specimen, it gives us a better idea of what is taking place at 
the cellular level, not only at the region of dysplasia, but also in the surrounding tissue.  
Depending on if the biopsy contained an area of surrounding normal tissue or not 
could also have impacted the scoring for a case. The goal of a good excisional biopsy is to 
take a surrounding region of normal tissue to ensure the entire lesion is removed. On the 
other hand, incisional biopsies often do not contain any surrounding normal tissue. The 
difficulty in this study is that in most cases, there was no way of confirming if the biopsy 
was incisional or excisional. This could also have impacted the scoring systems, as 
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incisional biopsies may be more prone to score higher than excisional biopsies using the 
manual scoring method and the automated (Straticyte) scoring method may be influenced 
less by the type of biopsy performed, because it is utilizing ROI hotspot locations, rather 
than the entire tissue specimen.  
Another possible reason for the inability to show Straticyte as a useful tool in 
predicting oral dysplasia progression could be that Straticyte is designed to predict 
progression over a 5-year period and not every case in our study was evaluated over a 5-
year period. This could be something for future studies in this area to consider.  
Another limitation of the study is the small sample size. We found it difficult to 
identify cases with multiple biopsies from a single site over time. Doing a multi-centre 
study would help to generate more cases and could be a solution to this limitation. 
Unfortunately, the attempt to obtain extended demographic and risk factor data did 
not yield useful results. Performing a prospective study would help in obtaining more 
comprehensive demographic data. 
 
5.8 Straticyte Potential 
The significant morbidity and mortality associated with OSCC and the low rate of 
transformation of OPMD creates a significant need for an objective biomarker to aid in 
differentiating high and low risk lesions [129]. 
The discovery of a reliable and accurate biomarker in predicting progression of 
potentially malignant oral lesions would aid in clinical decision making. It would reduce 
unnecessary surgery and instead direct surgery only to high-risk lesions.  
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Another utility is for patients who have multiple leukoplakia throughout the mouth. 
In such a case, a biomarker would allow targeted therapy only to high-risk lesions as 
excising all lesions would produce significant morbidity for the patient.  
Providing patients with a quantifiable risk from a diagnostic test, such as 
Straticyte may provide patients incentive for reducing risk factors such as smoking and 
drinking. Previous studies on the impact of lung cancer screening programs on smoking 
cessation have shown that a positive (abnormal finding) CT scan can encourage cessation 
[136, 137], however, persistently negative CT scans do not appear to reduce the likelihood 
of smoking cessation [138], suggesting that reassurance from negative tests does not 
encourage smoking. To our knowledge, there have been no studies evaluating the effects 
of Straticyte on risk factor reduction, however, this is an interesting area that would be 
worth exploring in future studies. 
A potential disadvantage of a biomarker is that it could provide a false sense of 
security. A patient that receives a report indicating/predicting a ‘low-risk’ lesion, may have 
no incentive for smoking cessation or alcohol abstinence. On the other hand, a clinician 
that receives a report for the same ‘low-risk’ lesion, may also not monitor the patient 
adequately, may not emphasize risk factor reduction, may not perform as thorough of a 
clinical examination as they otherwise should and may not arrange as strict of a 
surveillance regimen as they should.  
It is critical to always remember that biomarkers should only ever be used as 
adjunctive information to arrive at a clinical decision. There should be no substitute for a 
thorough history, physical examination, and perhaps histological assessment. The whole 
context of the patient needs to be considered. A good example of this is in the detection of 
 
 
100 
prostate cancer. A retrospective study found that digital rectal exam (DRE) was a clinically 
useful tool in detecting clinically significant prostate cancer in older Caucasian men when 
PSA levels were low (<2.5 ng/ml) [139]. This underscores the value of clinical examination 
in addition to a quantitative biomarker assessment.  
 Patients with low grade lesions, such as mild dysplasia as diagnosed by 
histopathology, are the ones that stand to benefit the most from a reliable objective 
biomarker test such as Straticyte, as clinical decision making is likely to change the most 
in patients with low-risk lesions.  Currently, most patients with mild dysplasia will be 
observed for clinical changes, however, an objective test suggesting that the lesion is higher 
risk, will likely lead to the lesion being removed. On the contrary, a severe dysplastic lesion, 
with a Straticyte score stating it is a low-risk lesion, is not likely to change the clinician’s 
decision to excise this lesion.  
For this reason, we think the utility of Straticyte needs to be evaluated for its 
predictive ability of each grade of dysplasia independently, to determine how best to 
employ the test. In other words, should the test be employed for all oral epithelial dysplasia 
or only for mild epithelial dysplasia? 
 The risk grouping Straticyte uses could also be potentially problematic for 
clinical care. A ‘low-risk’ lesion could still have a 5-year probability of cancer progression 
of 18%. Although this is considered a low-risk lesion by Straticyte, for the patient sitting 
in the chair, being told they have nearly a 1/5 chance of developing cancer in 5 years does 
not seem like low-risk.  
 The other problem we noticed was that the majority of the lesions in our study were 
classified as ‘intermediate-risk’ based on the Straticyte analysis. In the same way that the 
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binary system of histopathological diagnosis can be a useful tool for guiding clinical 
decision making, a Straticyte that was binary for only ‘low-risk’ and ‘high-risk’ lesions 
would likely also be a valuable decision-making tool.  
 
5.9 Importance of this study 
 The main importance of this study is to evaluate the diagnostic tool, Straticyte, 
by Proteocyte AI (Toronto, Ontario, Canada). Straticyte is a diagnostic test that is now 
being incorporated into clinical practice. To our knowledge, this is the first impartial study 
to evaluate Straticyte’s  usefulness.  Independent and unbiased studies evaluating the 
work and products from industry are important to gain a comprehensive understanding of 
their utility and safety. 
 The potential negative effects with widespread utilization if Straticyte has not yet 
been validated to be both accurate and precise are: 1) unnecessary surgery occurring; 2) 
relinquished surgery that should occur; 3) inappropriate follow-up schedule; and 4) 
unnecessary cost to the patient; many of which could lead to the inadvertent progression of 
disease.  
 On the contrary, if Straticyte proves to be both accurate and precise for predicting 
malignant transformation for oral pre-malignant disorders, this will  potentially lead to 
several benefits, such as: 1) more individualized patient care; 2) less surgery on low-risk 
lesions, resulting in less morbidity; 3) more surgery for high-risk lesions, leading to less 
advanced disease; 4) more appropriate resource utilization, such that high-risk patients 
would be seen at centers specialized in managing pre-malignant and malignant disease and 
low-risk patients would be followed in the community by generalists.  
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5.10 Future Studies/Work 
Further work with S100A7 is required to confirm that it is a useful biomarker in 
predicting progression of oral epithelial dysplasia. Additional studies should be performed 
to determine if S100A7 is useful in predicting transformation from oral dysplasia to SCC, 
and the expression of S100A7 in lichen planus lesions should also be evaluated to 
determine if a positive correlation exists with progression.  
If S100A7 proves to be an accurate and reliable marker of oral dysplasia 
progression, then a prospective study comparing the predictive power of the biomarker to 
the predictive power of a binary grading system using histopathological diagnosis would 
be valuable. To our knowledge, this has not yet been done.  
 S100A7 has also been speculated to have a protective function against invasion 
[100] and cyclin D1 has been suggested to be involved with invasion [134], therefore an 
IHC study evaluating the simultaneous expression of S100A7 and cyclin D1 could evaluate 
if decreasing expression of S100A7 is correlated with increased expression of cyclin D1 at 
the same site and time.  
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Chapter 6 
6.0 Conclusion 
 Our study did not show that S100A7 was a useful biomarker for predicting 
progression of oral dysplasia from a lower to a higher grade. This study also did not show 
that Straticyte was useful for predicting progression of oral dysplasia alone. As 
mentioned previously, this could be that Straticyte was designed to predict progression 
to malignancy. We believe that more unbiased and preferably prospective studies need to 
be conducted to determine the utility in predicting progression both of oral dysplasia and 
from oral dysplasia to malignancy before Straticyte should be incorporated into 
widespread clinical practice. In addition, the predictive power of Straticyte should be 
evaluated for various grades of dysplasia as there might not be a lot of value in applying it 
to all dysplastic lesions. We believe that if future studies show Straticyte to be an accurate 
and reliable diagnostic test, then the main utility would be in its application to low-risk 
lesions. 
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Appendix 
 
Raw Data 
 
Manual Scoring Method (Semi-quantitative & Qualitative) 
Total manual scoring of all biopsies for progressing cases of oral epithelial dysplasia 
Case  Biopsy 1 Score Biopsy 2 Score Biopsy 3 Score Biopsy 4 Score Biopsy 5 score 
1 7 8       
2 3 4       
3 5 6       
4 6 4       
5 5 5       
6 6 7       
7 5 7       
8 2 6       
9 5 6 6 7 8 
10 2 3       
11 3 5       
12 3 3       
12    3       
13 3 6       
14 0 2       
15 6 6 7     
16 8 7       
17 8 6       
18 6         
19 7 6       
20 3 6       
 
 
116 
21 6 4       
22 8 4       
23 8 7       
24 6 5       
 24   6       
25 3 2       
26 4 4       
27 4 5       
 27 5         
28 6 6 7 6   
29 5 2       
 
 
Total manual scoring of all biopsies for non-progressing cases of oral epithelial 
dysplasia 
Case  Biopsy 1 Score Biopsy 2 Score Biopsy 3 Score 
1 8 2   
2 3     
3 6 3   
4 5 5   
5 6 4   
6 4 3 2 
7 5 4   
8 8 3   
9 4 6   
10 3 6   
11 3 3   
12 4 5   
 
 
117 
13 5 7   
14 4 5   
 14 5     
15 5 4   
16 3 4   
17 6 5 5 
 
 
Total manual score of initial (and all) biopsies for control/normal/hyperkeratosis 
cases 
Case  Total Score 
1 5 
2 4 
3 3 
4 2 
5 7 
6 6 
7 3 
8 2 
9 3 
10 5 
11 3 
12 5 
13 5 
14 4 
15 4 
16 4 
17 3 
 
 
118 
18 2 
19 2 
20 4 
21 2 
22 2 
23 3 
24 3 
25 2 
 
 
 
Automated Scoring (Straticyte) 
Straticyte score of all biopsies for progressing cases of oral epithelial dysplasia 
Case  Biopsy 1 Score Biopsy 2 Score Biopsy 3 Score Biopsy 4 Score Biopsy 5 Score 
1 41.18 58.08       
2 0.00 32.03       
3 31.16 37.04       
4 19.09 24.98       
5 25.56 26.03       
6 21.27 20.10       
7 37.88 65.05       
8 13.87 52.71       
9 23.08 38.04 45.37 55.51 19.26 
10 10.36 13.19       
11 34.00 59.00       
12 5.38 2.75       
12    6.90       
 
 
119 
13 33.61 24.65       
14 5.07 12.11       
15 27.51 43.19 24.54     
16 36.53 64.05       
17 30.00 39.29       
18 17.09         
19 48.66 15.13       
20 16.15 29.35       
21 50.45 51.00       
22 67.45 38.83       
23 25.87 55.54       
24 21.04 26.54       
 24   38.72       
25 5.72 15.15       
26 22.84 16.37       
27 29.16 16.81       
 27 40.16         
28 26.48 18.02 24.80 39.45   
29 11.23 0.09       
 
 
Straticyte score of all biopsies for non-progressing cases of oral epithelial 
dysplasia 
Case  Biopsy 1 Score Biopsy 2 Score Biopsy 3 Score 
1 65.90 26.60   
2 16.00     
3 11.84 12.58   
4 26.18 61.02   
 
 
120 
5 23.01 23.93   
6 28.99 20.34 23 
7 9.00 12.91   
8 50.42 7.68   
9 11.65 19.11   
10 21.64 54.00   
11 42.00 50.00   
12 39.00 44.42   
13 50.00 53.00   
14 40.00 36.20   
 14 48.00     
15 71.00 72.00   
16 32.00 40.16   
17 41.75 51.00 55.40 
 
 
Straticyte score for initial (and all) biopsies of controls/normal/hyperkeratosis 
cases 
Case  Controls/Normal/Hyperkeratosis 
1 45.79 
2 37.67 
3 15.41 
4 20.15 
5 55.31 
6 30.57 
7 29.73 
8 22.17 
9 23.74 
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10 22.92 
11 17.73 
12 43.15 
13 40.11 
14 3.31 
15 18.44 
16 30.89 
17 50.66 
18 21.54 
19 24.22 
20 41.15 
21 20.54 
22 18.06 
23 51.12 
24 63.33 
25 18.59 
 
 
Straticyte scores with associated risk group for all biopsies of progressing cases of 
oral epithelial dysplasia 
Case  Biopsy 1 Score Risk Group 1 Biopsy 2 Score Risk Group 2 Biopsy 3 Score Risk Group 3 Biopsy 4 Score Risk Group 4 Biopsy 5 Score Risk Group 5 
1 41.18 Medium 58.08 Medium             
2 0.00 low 32.03 medium             
3 31.16 Medium 37.04 Medium             
4 19.09 Medium 24.98 Medium             
5 25.56 Medium 26.03 Medium             
6 21.27 Medium 20.10 Medium             
7 37.88 Medium 65.05 High             
 
 
122 
8 13.87 Low 52.71 Medium             
9 23.08 Medium 38.04 Medium 45.37 Medium 55.51 Medium 19.26 Medium 
10 10.36 Low 13.19 Low             
11 34.00 medium 59.00 medium             
12 5.38 low 2.75 low             
12      6.90 low             
13 33.61 Medium 24.65 Medium             
14 5.07 low 12.11 low             
15 27.51 Medium 43.19 Medium 24.54 Medium         
16 36.53 Medium 64.05 High             
17 30.00 medium 39.29 medium             
18 17.09 low                 
19 48.66 medium 15.13 low             
20 16.15 low 29.35 medium             
21 50.45 medium 51.00 medium             
22 67.45 High 38.83 Medium             
23 25.87 Medium 55.54 Medium             
24 21.04 medium 26.54 medium             
24      38.72 medium             
25 5.72 low 15.15 low             
26 22.84 medium 16.37 low             
27 29.16 medium 16.81 low             
27  40.16 medium                 
28 26.48 medium 18.02 low 24.80 medium 39.45 medium     
29 11.23 low 0.09 low             
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Straticyte scores with associated risk group for all biopsies of non-progressing 
cases of oral epithelial dysplasia 
Case  Biopsy 1 Score Risk Group 1 Biopsy 2 Score Risk Group 2 Biopsy 3 Score Risk Group 3 
1 65.90 high 26.60 medium     
2 16.00 low         
3 11.84 low 12.58 low     
4 26.18 medium 61.02 high     
5 23.01 medium 23.93 medium     
6 28.99 medium 20.34 medium 23.00 medium 
7 9.00 low 12.91 low     
8 50.42 medium 7.68 low     
9 11.65 low 19.11 medium     
10 21.64 medium 54.00 medium     
11 42.00 medium 50.00 medium     
12 39.00 medium 44.42 medium     
13 50.00 medium 53.00 medium     
14 40.00 medium 36.20 medium     
14  48.00 medium         
15 71.00 high 72.00 high     
16 32.00 medium 40.16 medium     
17 41.75 medium 51.00 medium 55.40 medium 
 
 
Straticyte scores with associated risk group for all biopsies of 
controls/normal/hyperkeratosis cases 
Case  Controls/Normal/Hyperkeratosis Risk Group 
1 45.79 medium 
2 37.67 medium 
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3 15.41 low 
4 20.15 medium 
5 55.31 medium 
6 30.58 medium 
7 29.73 medium 
8 22.17 medium 
9 23.73 medium 
10 22.93 medium 
11 17.73 low 
12 43.15 medium 
13 40.11 medium 
14 3.31 low 
15 18.44 low 
16 30.89 medium 
17 50.66 medium 
18 21.54 medium 
19 24.22 medium 
20 41.15 medium 
21 20.54 medium 
22 18.06 low 
23 51.12 medium 
24 63.33 high 
25 18.59 low 
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Initial Biopsy Only   
 
Manual Score 
 
Total manual score for initial biopsy of progressing cases of oral epithelial dysplasia. 
Case  Biopsy 1 Score 
1 7 
2 3 
3 5 
4 6 
5 5 
6 6 
7 5 
8 2 
9 5 
10 2 
11 3 
12 3 
13 3 
14 0 
15 6 
16 8 
17 8 
18 6 
19 7 
20 3 
21 6 
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22 8 
23 8 
24 6 
25 3 
26 4 
27 4 
 27 5 
28 6 
29 5 
 
 
Total manual score for initial biopsy of non-progressing cases of oral epithelial 
dysplasia. 
Case  Biopsy 1 Score 
1 8 
2 3 
3 6 
4 5 
5 6 
6 4 
7 5 
8 8 
9 4 
10 3 
11 3 
12 4 
13 5 
14 4 
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14  5 
15 5 
16 3 
17 6 
 
 
Automated Score with Risk and Area Calculation 
Straticyte score, risk group and area staining for initial biopsy of progressing 
cases of oral epithelial dysplasia. 
Case  Biopsy 1 Score Straticyte Risk Group Area 
1 41.18 Medium 0.54 
2 0.00 Low 0.17 
3 31.16 Medium 0.28 
4 19.09 Medium 0.16 
5 25.56 Medium 0.23 
6 21.27 Medium 0.38 
7 37.88 Medium unable to assess/complex tissue 
8 13.87 Low 0.03 
9 23.08 Medium 0.52 
10 10.36 Low 0.11 
11 34.00 Medium 0.16 
12 5.38 Low 0.14 
13 33.61 Medium 0.14 
14 5.07 Low 0.04 
15 27.51 Medium 0.55 
16 36.53 Medium 0.58 
17 30.00 Medium 0.69 
18 17.09 Low 0.40 
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19 48.66 Medium 0.42 
20 16.15 Low 0.02 
21 50.45 Medium 0.63 
22 67.45 High 0.65 
23 25.87 Medium 0.58 
24 21.04 Medium 0.63 
25 5.72 Low 0.29 
26 22.84 Medium 0.35 
27 29.16 Medium 0.39 
27  40.16 Medium 0.57 
28 26.48 Medium 0.67 
29 11.23 Low 0.34 
 
 
 
Straticyte score, risk category and area staining for initial biopsy of non-
progressing cases of oral epithelial dysplasia 
Case  Biopsy 1 Score Straticyte Risk Group Area 
1 65.90 High 0.94 
2 16.00 Low 0.01 
3 11.84 Low 0.35 
4 26.18 Medium 0.26 
5 23.01 Medium 0.51 
6 28.99 Medium 0.27 
7 9.00 Low 0.18 
8 50.42 Medium 0.44 
9 11.65 Low 0.33 
10 21.64 Medium 0.07 
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11 42.00 Medium 0.14 
12 39.00 Medium 0.19 
13 50.00 Medium 0.34 
14 40.00 Medium 0.32 
 14 48.00 Medium 0.73 
15 71.00 High 0.59 
16 32.00 Medium 0.16 
17 41.76 Medium 0.64 
 
 
 
 
Straticyte scoring for initial biopsy, risk category and area staining for 
controls/normal/hyperkeratosis cases 
Case  Controls/Normal/Hyperkeratosis Straticyte Risk Group Area 
1 45.79 Medium 0.43 
2 37.67 Medium 0.20 
3 15.41 Low 0.11 
4 20.15 Medium 0.01 
5 55.31 Medium 0.93 
6 30.58 Medium 0.57 
7 29.73 Medium 0.08 
8 22.17 Medium 0.03 
9 23.74 Medium 0.03 
10 22.93 Medium 0.17 
11 17.73 Low 0.05 
12 43.15 Medium 0.22 
13 40.11 Medium 0.53 
 
 
130 
14 3.31 Low 0.19 
15 18.44 Low 0.04 
16 30.89 Medium 0.25 
17 50.66 Medium 0.28 
18 21.54 Medium 0.03 
19 24.22 Medium 0.12 
20 41.15 Medium 0.28 
21 20.54 Medium 0.01 
22 18.06 Low 0.03 
23 51.12 Medium 0.22 
24 63.33 High 0.42 
25 18.59 Low 0.06 
 
 
 
Binary Scoring System 
WHO binary scoring of initial biopsy for non-progressing cases.  
Case  Diagnosis Binary Score MD Binary Score LM 
1 moderate to severe dysplasia  high high 
2 Mild atypia with hyperkeratosis low low 
3 Mild to moderate dysplasia low high 
4 moderate to severe dysplasia high high 
5 moderate to severe dysplasia with focal CIS high high 
6 mild to moderate dysplasia high high 
7 Verrucous hyperplasia with early verrucous carcinoma no grade no grade 
8 mild dysplasia low high 
9 moderate dysplasia high high 
10 hyper-orthokeratosis with mild dysplasia high low 
11 mild dysplasia low low 
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12 moderate dysplasia high high 
13 mild dysplasia low low 
14 amalgam tattoo no grade no grade 
15 mild to moderate dysplasia high low 
16 Mild to moderate dysplasia high high 
17 verrucous hyperplasia with moderate epithelial dysplasia high high 
18 moderate dysplasia high high 
19 mild dysplasia high high 
20 mild dysplasia low low 
21 mild dysplasia low high 
22 severe dysplasia high high 
23 mild to moderate dysplasia high high 
24 moderate dysplasia high high 
25 mild dysplasia high high 
26 mild dysplasia high low 
27 mild dysplasia  Unable to locate Unable to locate 
 27 mild dysplasia  Unable to locate Unable to locate 
28 mucositis with hyperorthokeratosis high low 
29 severe dysplasia high high 
 
 
WHO binary scoring of initial biopsy for non-progressing cases 
Case  Diagnosis Binary Score MD Binary Score LM 
1 moderate to severe dysplasia low low 
2 mild dysplasia low  low 
3 CIS high high 
4 moderate dysplasia high high 
5 moderate to severe dysplasia high high 
6 
hyperparakeratosis with chronic 
mucositis  low low 
7 moderate to severe dysplasia high high 
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8 moderate dysplasia high high 
9 moderate dysplasia high high 
10 mild dysplasia high low 
11 mild dysplasia low low 
12 mild dysplasia low low 
13 mild dysplasia 
lichenoid mucositis/arch 
atypia 
lichenoid mucositis/arch 
atypia 
14 
hyperkeratosis with mild epithelial 
atypia and chronic mucositis  low low 
 14 
hyperkeratosis with mild epithelial 
atypia    
hyperkeratosis/chronic 
mucositis 
hyperkeratosis/chronic 
mucositis 
15 mild dysplasia low low 
16 mild dysplasia low low 
17 mild dysplasia  Unable to locate Unable to locate 
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Lachlan McLean, BSc, DMD, MD 
Oral and Maxillofacial Surgery Resident (PGY6), London Health Sciences Centre, 
London, ON, CANADA 
 
Education            
Oral & Maxillofacial Surgery (OMFS) Residency – Western University/London Health Sciences Center     Anticipated 2020 
Masters of Pathology, Western University/Pathology and Laboratory Medicine                                           Anticipated 2019 
Doctor of Medicine, Western University/Schulich School of Medicine & Dentistry                           2019 
OMFS Internship – John Peter Smith Hospital, Fort Worth, Texas                                                        2014 
Doctor of Dental Medicine, University of British Columbia                                                                        2013  
Bachelor of Science, Thompson Rivers University                                           2008 
Athol Murray College of Notre Dame (high school), Wilcox, SK                             2003 
Research             
Thesis:  
“Evaluating the Utility of Protein Biomarker S100A7, as a Predictor for the Progression of Oral Dysplasia”                          Anticipated 2019 
Supervisor: Dr. Mark Darling, DDS (Oral Pathologist)    
Publications            
McLean, L, Soparlo, J, Armstrong, J. Displaced Teeth at the Time of Surgery. Oral Health. June 5th, 2017. 
 
Darling, M, Hassan, A, McLean, L. Psoriasin: A New Biomarker in the Identification of Cancer Risk in Oral Lesions. Oral 
Health. December, 2018.  
 
Presentations            
Pathology and Laboratory Medicine Research Day             2016 
“Evaluating the Utility of Protein Biomarker S100A7, as a Predictor for the Progression of Oral Dysplasia” 
 
International Association for Dental Research (IADR) Annual Meeting, San Francisco, CA          2017 
“S100A7 Expression Indicates Risk of Progression of Oral Epithelial Dysplasia” 
 
International Association of Oral Pathology/American Association of Oral Medicine &           2018 
Pathology Joint Conference, Vancouver, BC   
“Evaluating the Utility of Protein Biomarker S100A7, as a Predictor for the Progression of Oral Dysplasia” 
 
Ontario Society of Oral and Maxillofacial Surgeons Residents Night            2018 
“Zygomatic Implants: Utilization in Post-Maxillectomy Rehabilitation”  
 
LHSC Emergency Department Residents               2019 
“Oral and Maxillofacial Surgery and Dental Emergencies in the Emergency Department” 
 
Professional Associations           
Ontario Dental Association                  2014 – Present 
Ontario Medical Association                  2017 – Present 
Canadian Medical Association                  2017 - Present 
London District Dental Society                  2014 – Present 
Canadian Association of Oral and Maxillofacial Surgeons (CAOMS)              2014 – Present 
Canadian Residents Association of Oral and Maxillofacial Surgeons (CRAOMS)             2014 – Present 
American Association of Oral and Maxillofacial Surgeons (AAOMS)              2014 - Present 
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Awards and Scholarships           
Outstanding OMFS Intern, John Peter Smith Hospital              2014 
 
British Columbia Association of Oral & Maxillofacial Surgeons Book Award            2013 
 
American Academy of Craniofacial Pain Senior Student Award             2013 
 
Dean’s Honor Roll, University of British Columbia                                             2010, 2011, 2013 
Awarded to students having achieved an overall grade of >85% during the academic year 
 
Susan Foy Memorial Award                                 2011 
Awarded to a student who exhibits good academic standing, leadership qualities, community service  
involvement and an interest in oral surgery and pediatrics 
 
Dean’s Honor Roll, Thompson Rivers University                                                            2005, 2006, 2007 
Awarded to students having achieved a GPA of at least 3.7 (4.3 scale) while maintaining at least 80% of a full  
course load 
 
Provost Leadership and Physiology Award                                2007 
Awarded to a student who exhibits strong leadership characteristics and has demonstrated a special aptitude for 
human physiology 
 
Volunteer Work            
Ark Aid Street Mission, London, Ontario                 2016 
Site Chief for a Student Run Volunteer Dental Clinic, Abbotsford, BC                                               2010  
Student Dentist Volunteer, East Vancouver, BC                                2010  
CHIUS - Downtown Eastside Medical Clinic, East Vancouver, BC               2009 
Big Brothers & Big Sisters, Kamloops, BC                                              2007-2009 
Coached at the Track and Field Club, Kamloops, BC                     2005-2006 
Prepared and Served Food at the New Life Mission Homeless Shelter, Kamloops, BC                  2006-2008 
St. John Ambulance Brigade 518, Kamloops, BC                                            2007-2008 
Athletics             
Team Saskatchewan U-17 Field Lacrosse Team, Saskatoon, SK                              2001 
Kamloops Track and Field Club, Kamloops, BC                                            2003-2006 
Golf                               Present 
Intramurals Recreation Ice Hockey for Western Medicine                          Present 
  
 
